<SEC-DOCUMENT>0001213900-25-016103.txt : 20250221
<SEC-HEADER>0001213900-25-016103.hdr.sgml : 20250221
<ACCEPTANCE-DATETIME>20250221161508
ACCESSION NUMBER:		0001213900-25-016103
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250215
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250221
DATE AS OF CHANGE:		20250221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		25652071

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0231758-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ATNF="http://180lifesciences.com/20250215">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ATNF_180lifesciences.com_20250215 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20250215_20250215 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="text-indent: 0.25in; display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000004" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20250215.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-02-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-15</xbrli:startDate>
        <xbrli:endDate>2025-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-15</xbrli:startDate>
        <xbrli:endDate>2025-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-15</xbrli:startDate>
        <xbrli:endDate>2025-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM&#160;<span id="xdx_90C_edei--DocumentType_c20250215__20250215_z9FV3WF1F5kg"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date of
earliest event reported):&#160;<b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20250215__20250215_z8nnbvRbuj91"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">February 15, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20250215__20250215_zaCkMFSFgNQ2"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000011" name="dei:EntityRegistrantName">180 LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20250215__20250215_zh2tvunzrwc"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20250215__20250215_zFjoDmPAGQd9"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000013" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20250215__20250215_zyRyn8SBJEOk"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000014" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20250215__20250215_zGU1VYjMFvEe"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000015" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>,<span id="xdx_909_edei--EntityAddressAddressLine2_c20250215__20250215_z7MdXSuwUz8c"> <ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000016" name="dei:EntityAddressAddressLine2">Bldg. 4</ix:nonNumeric></span>,<span id="xdx_900_edei--EntityAddressAddressLine3_c20250215__20250215_z7vPZtHLeWF3"> <ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000017" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20250215__20250215_zF0YZJ9VX8vl"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000018" name="dei:EntityAddressCityOrTown">Palo Alto</ix:nonNumeric></span>,&#160;<span id="xdx_90F_edei--EntityAddressStateOrProvince_c20250215__20250215_zmrnX9mEcJi9"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000019" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20250215__20250215_zeiwLCH7muOg"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000020" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b><span style="text-decoration: underline">(<span id="xdx_90B_edei--CityAreaCode_c20250215__20250215_z2f3QV9es7Gj"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000021" name="dei:CityAreaCode">650</ix:nonNumeric></span>)&#160;<span id="xdx_90D_edei--LocalPhoneNumber_c20250215__20250215_zmYyQF6YBTNa"><ix:nonNumeric contextRef="AsOf2025-02-15" id="Fact000022" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see</i>&#160;General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--WrittenCommunications_c20250215__20250215_zYO29rCgC9me"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20250215__20250215_zNXWgGvK0pr3"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20250215__20250215_zJrE7PQC3Yj8"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20250215__20250215_zBdU1onmO2Hf"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e 4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20250215__20250215__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zeJSATgGAESh"><ix:nonNumeric contextRef="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20250215__20250215__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zD0ZzrE5ZDl"><ix:nonNumeric contextRef="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember" id="Fact000028" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The&#160;<span id="xdx_902_edei--SecurityExchangeName_c20250215__20250215__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zO8Tp4K7hHL8"><ix:nonNumeric contextRef="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20250215__20250215__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_z1WyCCUzCB0k"><ix:nonNumeric contextRef="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000030" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20250215__20250215__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zaJCnRDtXt15"><ix:nonNumeric contextRef="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000031" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The&#160;<span id="xdx_906_edei--SecurityExchangeName_c20250215__20250215__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zzsBq7YgHi38"><ix:nonNumeric contextRef="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250215__20250215_zJGqwUIXzC88"><ix:nonNumeric contextRef="AsOf2025-02-15" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(c)&#160;Appointment of Chief Accounting Officer
(Principal Accounting/Financial Officer)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on February 15,
2025, the Board of Directors of 180 Life Sciences Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;, &#8220;<span style="text-decoration: underline">we</span>&#8221; and &#8220;<span style="text-decoration: underline">us</span>&#8221;),
appointed Eric R. Van Lent as the Chief Accounting Officer (Principal Accounting/Financial Officer)&#160;of the Company (the &#8220;<span style="text-decoration: underline">Appointment</span>&#8221;),
which Appointment was effective as of the same date. As a result of the Appointment, Blair Jordan, the Chief Executive Officer (Principal
Executive Officer)&#160;of the Company, who had served as the Principal Accounting/Financial Officer of the Company since October 16,
2024, stepped down from such role, also effective on February 15, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Van Lent is not party
to any material plan, contract or arrangement (whether or not written)&#160;with the Company, except for the EVL Consulting Agreement
(discussed and described below), and there are no arrangements or understandings between Mr. Van Lent and any other person pursuant to
which Mr. Van Lent was selected to serve as a director or officer of the Company, nor is Mr. Van Lent a participant in any related party
transaction required to be reported pursuant to Item 404(a)&#160;of Regulation S-K. There are no family relationships between any director
or executive officer of the Company, including Mr. Van Lent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company plans to enter
into a standard form of Indemnity Agreement (the &#8220;<span style="text-decoration: underline">Indemnification Agreement</span>&#8221;)&#160;with Mr. Van Lent in connection
with the Appointment. The Indemnification Agreement provides, among other things, that the Company will indemnify Mr. Van Lent under the
circumstances and to the extent provided for therein, for certain expenses he may be required to pay in connection with certain claims
to which he may be made a party by reason of his position as an officer of the Company, and otherwise to the fullest extent permitted
under Delaware law and the Company&#8217;s governing documents. The foregoing is only a brief description of the Indemnification Agreement,
does not purport to be complete and is qualified in its entirety by the Company&#8217;s standard form of indemnification agreement incorporated
by reference herein as&#160;<span style="text-decoration: underline">Exhibit 10.4</span>. The Indemnification Agreement is identical in all material respects to the indemnification
agreements entered into with other Company officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any director or executive officer of the Company, including Mr. Van Lent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biographical information for
Mr. Van Lent is provided below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Eric R. Van Lent, age 42:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Eric R. Van Lent is a seasoned
finance and accounting professional with over 20 years of experience optimizing financial operations, streamlining processes, and driving
revenue growth in medium to large organizations. With expertise spanning financial reporting, strategic planning, and enterprise resource
planning (ERP)&#160;implementation, he has played a pivotal role in enhancing operational efficiency and profitability across manufacturing,
distribution, software, defense, &amp; Esports industries. Mr. Van Lent has served as a NetSuite advanced financials consultant with Cumula3
Group since February 2024 and as the managing member of his own consulting firm, EVL Consulting LLC, since February 2020. Mr. Van Lent
previously served as Vice President and Corporate Controller of Engine Media Holdings, Inc., a software/gaming/racing/esports company
from January 2018 to December 2021. In that role, he managed the restructuring and financial oversight of a multi-site international software
business. He played a key role in the company's successful uplisting from the TSX Venture Exchange to Nasdaq and led the implementation
of NetSuite ERP, streamlining financial reporting across multiple global operations. Mr. Van Lent has also held positions at&#160;Assa
Abloy, Lockheed Martin, and Flight Line Products, where he successfully executed ERP integrations, automated financial processes, and
led cost-reduction initiatives, achieving multimillion-dollar savings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Van Lent holds a&#160;Master
of Business Management in Finance from Norwich University&#160;and a&#160;Bachelor of Business Management from Pepperdine University.
He is a&#160;Certified Public Accountant (CPA)&#160;licensed in California. He also Served in the United States Navy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on February 15,
2025, the Company entered into an Executive Consulting Agreement dated January 30, 2025 with Mr. Van Lent and EVL Consulting, LLC (an
entity owned by Mr. Van Lent)(&#8220;<span style="text-decoration: underline">EVL Consulting</span>&#8221; and the &#8220;<span style="text-decoration: underline">EVL Consulting Agreement</span>&#8221;). Pursuant to
the EVL Consulting Agreement, the Company agreed to engage EVL Consulting to provide the services of Mr. Van Lent to the Company as Chief
Accounting Officer of the Company. The EVL Consulting Agreement has a term through July 30, 2025, unless otherwise terminated pursuant
to the terms of the agreement (discussed below)&#160;and provides for Mr. Van Lent to act as Chief Accounting Officer of the Company,
and to be paid $8,000 per month for an average of 10 hours of work per week, with any hours in excess of that amount being compensated
at the rate of $200 per hour, only if preapproved in writing by the Company. Notwithstanding the above, the Board of Directors, with the
recommendation of the Compensation Committee, may grant Mr. Van Lent bonuses from time to time in its discretion, in cash or equity. The
EVL Consulting Agreement includes customary confidentiality, non-disclosure and proprietary right requirements of EVL Consulting and Mr.
Van Lent, and a prohibition on EVL Consulting and Mr. Van Lent competing against us during the term of the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have the right to terminate
the EVL Consulting Agreement at any time, provided that we pay EVL Consulting $10,000 upon such termination, payable within 60 days of
such termination date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also able to terminate
the EVL Consulting Agreement at any time, without notice upon: (a)&#160;the death or physical or mental incapacity of Mr. Van Lent if
as a result of which Mr. Van Lent is unable to perform services for a period in excess of 30 days; (b)&#160;in the event Mr. Van Lent
or a related party to Mr. Van Lent ceases to own or control 100% of EVL Consulting; or (c)&#160;&#8220;<span style="text-decoration: underline">just cause</span>&#8221;, which
means any of the following events: (i)&#160;any material or persistent breach by EVL Consulting or Mr. Van Lent of the terms of the agreement;
(ii)&#160;the conviction of EVL Consulting or Mr. Van Lent of a felony offence, or the equivalent in a non-American jurisdiction, or of
any crime involving moral turpitude, fraud or misrepresentation, or misappropriation of money or property of the Company or any affiliate
of the Company; (iii)&#160;a willful failure or refusal by EVL Consulting or Mr. Van Lent to satisfy its respective obligations to the
Company under the agreement including without limitation, specific lawful directives, reasonably consistent with the agreement, or requests
of the Board; (iv)&#160;any negligent or willful conduct or omissions of EVL Consulting or Mr. Van Lent that directly results in substantial
loss or injury to the Company; (v)&#160;fraud or embezzlement of funds or property, or misappropriation involving the Company&#8217;s
assets, business, customers, suppliers, or employees; (vi)&#160;any failure to comply with any of the Company&#8217;s written policies
and procedures, including, but not limited to, the Company&#8217;s Corporate Code of Ethics and Insider Trading Policy, provided that
subject to certain limited exceptions, we must first give written notice to EVL Consulting and Mr. Van Lent, as applicable, advising them
of the acts or omissions that constitute failure or refusal to perform their obligations and that failure or refusal continues after EVL
Consulting and Mr. Van Lent, as applicable, has had thirty (30)&#160;days to correct the acts or omissions as set out in the notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company terminates
the EVL Consulting Agreement for just cause, we are required to pay EVL Consulting any unpaid fees and/or unpaid and unreimbursed expenses
accrued but unpaid prior to the effective termination date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary of the
EVL Consulting Agreement and Indemnification Agreement is a summary only and is qualified in its entirety by reference to the EVL Consulting
Agreement and Indemnification Agreement, copies of which are attached hereto (or incorporated by reference herein)&#160;as&#160;<span style="text-decoration: underline">Exhibits
10.1</span>&#160;and&#160;<span style="text-decoration: underline">10.4</span>, respectively and are incorporated into this&#160;<span style="text-decoration: underline">Item 5.02</span>&#160;by reference in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(e) Executive Consulting Agreement with Blair
Jordan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, the Company
entered into an Executive Consulting Agreement with Mr. Blair Jordan dated February 21, 2024, the Company&#8217;s Chief Executive Officer
and director, and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan)(&#8220;<span style="text-decoration: underline">Jordan
Consulting</span>&#8221; and the &#8220;<span style="text-decoration: underline">Jordan Consulting Agreement</span>&#8221;). The Jordan
Consulting Agreement replaced and superseded a prior Executive Consulting Agreement with Mr. Jordan and Jordan Consulting dated May 7,
2024 (the &#8220;<span style="text-decoration: underline">Prior Agreement</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Jordan Consulting
Agreement, the Company agreed to continue to engage Jordan Consulting to provide the services of Mr. Jordan to the Company as Chief Executive
Officer of the Company. The Jordan Consulting Agreement has a term beginning effective January 1, 2025, and continuing through December
31, 2026, unless otherwise terminated pursuant to the terms of the agreement (discussed below), provided that in the event that the parties
have not agreed to an extension or termination of the Jordan Consulting Agreement with at least 30 days written notice at the end of the
term, the agreement automatically renews for successive terms of one year upon the expiration of the primary term or any renewal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Jordan Consulting Agreement
provides for Mr. Jordan to act as Chief Executive Officer of the Company, and to be paid $240,000 per year (previously Mr. Jordan was
paid $216,000 per year under the Prior Agreement) in consideration for services rendered to the Company (the &#8220;<span style="text-decoration: underline">Fee</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The agreement also allows the
Company to pay Mr. Jordan or Jordan Consulting an incentive bonus of up to 100% of the Fee per year, in the form of cash or equity, in
the discretion of the Compensation Committee and the Board. Any additional bonus payments in 2025, if any, and subsequent bonus payments
in 2026 from the Company to the Mr. Jordan or Jordan Consulting, if any, will be based on criteria to be determined by the Compensation
Committee of the Board. The Board and Compensation Committee may also pay Mr. Jordan or Jordan Consulting bonuses from time to time in
cash or equity, in their sole discretion, with any bonus earned being paid by March 15th of the year following the date it is earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also agreed to grant 160,000
shares of restricted common stock (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), to Mr. Jordan under the
Company&#8217;s Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (the &#8220;<span style="text-decoration: underline">Incentive
Plan</span>&#8221;), with such Shares to be evidenced and documented by a Notice of Restricted Stock Grant and Restricted Stock Grant
Agreement to be entered into between Mr. Jordan and the Company, and subject to vesting as follows: (a) 80,000 Shares vest on January
1, 2026, subject to Mr. Jordan&#8217;s continued service to the Company on such vesting date; and (b) 80,000 Shares vest on December 31,
2026, subject to Mr. Jordan&#8217;s continued service to the Company on such vesting date. In the event that the agreement is terminated
by us without &#8220;cause&#8221; or by Jordan Consulting for &#8220;good reason&#8221;, the Shares and all options and shares then outstanding
and scheduled to vest within one year of termination will immediately vest, and (iii) the treatment of the Shares and all options and
shares then outstanding and scheduled to vest outside of one year from termination will be determined solely by the Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Jordan Consulting Agreement
includes customary confidentiality, non-disclosure and proprietary right requirements of Jordan Consulting and Mr. Jordan, and a prohibition
on Jordan Consulting and Mr. Jordan competing against us during the term of the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Jordan Consulting may terminate
the Jordan Consulting Agreement at any time for &#8220;<span style="text-decoration: underline">good reason</span>&#8221; as described in the Jordan Consulting Agreement, subject
to certain cure rights; at any time without &#8220;<span style="text-decoration: underline">good reason</span>&#8221;; and upon expiration of the term or any renewal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate the Jordan
Consulting Agreement at any time for &#8220;<span style="text-decoration: underline">just cause</span>&#8221; (as described below) and for any reason other than &#8220;<span style="text-decoration: underline">just
cause</span>&#8221;. &#8220;J<span style="text-decoration: underline">ust cause</span>&#8221; means the occurrence of any of the following events: (i) any material or persistent
breach by Jordan Consulting or Mr. Jordan of the terms of the agreement; (ii) the conviction of Jordan Consulting or Mr. Jordan of a felony
offence, or the equivalent in a non-American jurisdiction, or of any crime involving moral turpitude, fraud or misrepresentation, or misappropriation
of money or property of the Company or any affiliate of the Company; (iii) a willful failure or refusal by Jordan Consulting or Mr. Jordan
to satisfy its respective obligations to the Company under the agreement including without limitation, specific lawful directives, reasonably
consistent with the agreement, or requests of the Board; (iv) any negligent or willful conduct or omissions of Jordan Consulting or Mr.
Jordan that directly results in substantial loss or injury to the Company; (v) fraud or embezzlement of funds or property, or misappropriation
involving the Company&#8217;s assets, business, customers, suppliers, or employees; (vi) any failure to comply with any of the Company&#8217;s
written policies and procedures, including, but not limited to, the Company&#8217;s Corporate Code of Ethics and Insider Trading Policy,
provided that subject to certain limited exceptions, we must first give written notice to Jordan Consulting and Mr. Jordan, as applicable,
advising them of the acts or omissions that constitute failure or refusal to perform their obligations and that failure or refusal continues
after Jordan Consulting and Mr. Jordan, as applicable, has had thirty (30) days to correct the acts or omissions as set out in the notice,
if such acts are correctable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also able to terminate
the Jordan Consulting Agreement at any time, without notice upon: (a) the death or physical or mental incapacity of Mr. Jordan if as a
result of which Mr. Jordan is unable to perform services for a period in excess of 60 days; or (b) in the event Mr. Jordan or a related
party to Mr. Jordan ceases to own or control 100% of Jordan Consulting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the agreement is terminated
by Jordan Consulting for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, or by the Company without &#8220;<span style="text-decoration: underline">just cause</span>&#8221; (other than due to
death or disability), Jordan Consultant is required to be paid, in a lump sum on the thirtieth day following such termination, a severance
payment equal to (i) half of the then current annualized Fee, in the event such termination occurs during the first twelve months of the
agreement and 100% of the then current annualized Fee, in the event such termination occurs after the first twelve months of the Agreement,
together with all outstanding expenses and pro-rated Fee (through the date of termination); (ii) any unpaid annual cash bonus in respect
of any completed fiscal year that has ended prior to the date of such termination with such amount determined based on actual performance
during such fiscal year as determined by the compensation committee; and (iii) immediate vesting of any and all equity or equity-related
awards previously awarded. Any equity awards that vest based on various performance metrics will be vested only if such performance metrics
have been met at the time of termination of service and will be determined solely by the Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the agreement is terminated
without &#8220;<span style="text-decoration: underline">good reason</span>&#8221; by Jordan Consulting or for &#8220;<span style="text-decoration: underline">just cause</span>&#8221; by the Company, Jordan Consulting
is entitled to the Accrued Liabilities (as defined below), and any equity awards or equity-related awards that are not vested as of the
date of termination will be cancelled and forfeited and any vested awards will be exercisable pursuant to their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the agreement is terminated
due to Mr. Jordan&#8217;s death or disability, Jordan Consulting or Mr. Jordan&#8217;s estate or his beneficiaries, as the case may be,
will be entitled to receive (i) any accrued but unpaid Fee through the date of termination, any unpaid or unreimbursed expenses incurred
in accordance with the terms of the agreement, (collectively, the &#8220;<span style="text-decoration: underline">Accrued Liabilities</span>&#8221;); (ii) any unpaid annual cash
bonus in respect of any completed fiscal year that has ended prior to the date of such termination, with such amount determined based
on actual performance during such fiscal year as determined by the Company&#8217;s Compensation Committee on the sixtieth day following
termination; (iii) a lump sum payment of any non-discretionary annual cash bonus that would have been payable based on actual performance
with respect to the year of termination in the absence of Mr. Jordan&#8217;s death or disability, pro-rated for the period that Mr.
Jordan worked prior to his death or disability, and payable at the same time as the bonus would have been paid in the absence of Mr. Jordan&#8217;s
death or disability; and (iv) immediate vesting of any and all equity or equity-related awards previously awarded to Jordan Consulting,
irrespective of the type of award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition precedent to
payment of any amount or provision of any benefit to Mr. Jordan upon termination (the &#8220;<span style="text-decoration: underline">Severance Benefits</span>&#8221;), Jordan
Consulting and Mr. Jordan or Mr. Jordan&#8217;s estate, as applicable, shall execute and shall not rescind, a release in favor of the
Company and all related companies, individuals, and entities, in a form satisfactory to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon termination of the agreement
or for any reason other than &#8220;<span style="text-decoration: underline">good reason</span>&#8221; by Jordan Consulting or the Company
without &#8220;<span style="text-decoration: underline">just cause</span>&#8221;, Jordan Consulting and Mr. Jordan agreed that, for a
period ending six months from the date of termination, Jordan Consulting and Mr. Jordan shall not (except on behalf of the Company or
with the prior written consent of the Company), directly or indirectly, compete with the Company for a period of one year, neither Mr.
Jordan, nor Jordan Consulting shall solicit employees or consultants of the Company, each as discussed in greater detail in the Jordan
Consulting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;The foregoing summary
of the Jordan Consulting Agreement and Notice of Restricted Stock Grant and Restricted Stock Grant Agreement is a summary only and is
qualified in its entirety by reference to the Jordan Consulting Agreement and form of Notice of Restricted Stock Grant and Restricted
Stock Grant Agreement, copies of which are attached hereto as&#160;<span style="text-decoration: underline">Exhibits 10.2</span>&#160;and&#160;<span style="text-decoration: underline">10.3</span>, respectively and are
incorporated into this&#160;<span style="text-decoration: underline">Item 5.02</span>&#160;by reference in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Item
8.01 Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Executive Director Restricted Stock Awards</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">On February 20, 2025, the Company issued, after recommendation by the Compensation
Committee of the Company&#8217;s Board of Directors and approval by the Board of Directors, in addition to the Equity Grant to Mr. Jordan
discussed in <span style="text-decoration: underline">Item 5.02</span>, above, 65,000 shares of restricted common stock to each of the Company&#8217;s four non-executive members
of the Board of Directors under the Incentive Plan, which vest at the rate of 1/2 of such shares on each of July 1, 2025 and December
31, 2025, subject to such persons continued service to the Company on the applicable vesting dates. The grants will be evidenced by Notice
of Restricted Stock Grants and Restricted Stock Grant Agreements entered into between the Company and each recipient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">The description of the
Notice of Restricted Stock Grants and Restricted Stock Grant Agreements above is not complete and is qualified in its entirety by
the form of Notice of Restricted Stock Grant and Restricted Stock Grant Agreement, which is attached as&#160;<span style="text-decoration: underline">Exhibit
10.3</span>&#160;hereto and incorporated by reference into this&#160;<span style="text-decoration: underline">Item&#160;8.01</span>&#160;in
its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Item 9.01 Financial Statements
and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><span style="font-size: 10pt">10.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea023175801ex10-1_180life.htm"><span style="font-size: 10pt">Executive Consulting Agreement entered into on February 15, 2025 and effective January 30, 2025, by and between 180 Life Sciences Corp., Eric Van Lent and EVL Consulting, LLC</span></a></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.2*</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea023175801ex10-2_180life.htm"><span style="font-size: 10pt">Executive Consulting Agreement dated February 21, 2025, by and between 180 Life Sciences Corp., Blair Jordan and Blair Jordan Strategy and Finance Consulting Inc.</span></a></td></tr>
  <tr style="background-color: #CCECFF">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.3*</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea023175801ex10-3_180life.htm"><span style="font-size: 10pt">Form of Notice of Restricted Stock Grant and Restricted Stock Grant Agreement (February 2025 Officer and Director Grants)</span></a></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1690080/000121390024041030/ea020558901ex10-6_180lifesci.htm"><span style="font-size: 10pt">Form of 180 Life Sciences Corp. Indemnity Agreement&#160;(Filed as Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2024), and incorporated herein by reference)</span></a></td></tr>
  <tr style="background-color: #CCECFF">
    <td><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL documents).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: February 21, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;&#160;</span></td>
    <td style="width: 30%"><span style="font-size: 10pt">Blair Jordan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">6</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kdFqwjAUhp/AdziUXYqmAcfo3VacjOlWVHS3sT2dwTannKROH2lvuTRV5sUWAuFwzvf//yFRNIxm9KwrZPh4Ws5hjXVTKYewxBIZTY5+In15TcC/S/zU1rEyLpRXMCXPoGcmIznZ+UYYPWqLRQJCjqUYywmIh0TcQ7aIBl0/JVPqAo3TqgJlCsiYGtboFJ97hbU6kaH6HKw2yFaTSSAeib79DVLEEt7oqL6IDxbm8zQaDMMZRDOmtvFT05ND05EwrbD2dranf29Ik7fWUZ1sFXfL2TVlLed7ZXG1V4z2vfQr1mRWjvLDAusdsodiIWUsHi95riw4guZCgw04UAm9AASFP5xv9DPFG1W1KEZCiDhDDhn+cb2VHUKjGI4dC3c9DY3/nhDi6vkDbFWWBQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea023175801ex10-1_180life.htm
<DESCRIPTION>EXECUTIVE CONSULTING AGREEMENT ENTERED INTO ON FEBRUARY 15, 2025 AND EFFECTIVE JANUARY 30, 2025, BY AND BETWEEN 180 LIFE SCIENCES CORP., ERIC VAN LENT AND EVL CONSULTING, LLC
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 10.1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE CONSULTING AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">made this 30 day of January, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AMONG</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EVL CONSULTING, LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ERIC VAN LENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 92%; text-align: right"></td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>Page</b></font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 1 INTERPRETATION</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>2</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Interpretation</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Engagement</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Term</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">3</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Title</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">3</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Responsibilities</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">3</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">General Responsibilities</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">3</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 2 COMPENSATION</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>4</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Fees</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Incentive Bonus</font></td>
    <td style="text-align: center"></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Vesting of Options and RSUs</font></td>
    <td style="text-align: center"></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Expenses and Fees</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Independent Contractor</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 3 THE CONSULTANT&rsquo;s and THE CAO&rsquo;s ADDITIONAL COVENANTS and representations</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>5</b></font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Confidential Information</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">5</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No Disclosure</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">6</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No Competition &amp; Notice of Conflict</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">6</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Company&rsquo;s Proprietary Rights</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Special Remedies</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">The Consultant&rsquo;s Representations</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 4 TERMINATION</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>8</b></font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Payment of Amounts Due</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination for Just Cause and Other Events of Early Termination</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Effect on Termination under Section 4.5</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Effect on Benefits</font></td>
    <td style="text-align: center"></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Return of Property</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Resignation of Director and Officer</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 5 RESOLUTION OF DISPUTES</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>10</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Mediation</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 6 GENERAL</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>11</b></font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Further Assurances</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Assignment</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Severability</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Waiver and Consent</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Notice</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Binding Effect</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Governing Law</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Time of Essence</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">13</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Counterparts</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">13</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Entire Agreement</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">13</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Survival of Terms</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">13</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE CONSULTING AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>THIS AGREEMENT</b> is dated for reference and
made effective the 30 day of January 2025 (the &ldquo;Effective Date&rdquo;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AMONG:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><b>180 LIFE SCIENCES CORP.,</b> a corporation
duly incorporated under the laws of Delaware, having a place of business at 3000 El Camino Real, Bldg. 4, Suite 200 Palo Alto, CA</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;<b>Company</b>&rdquo;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">OF THE FIRST PART</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AND:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><b>EVL CONSULTING, LLC<font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">.,
</font></b>a corporation duly incorporated under the laws of Wyoming, having offices at 312 W 2nd St, Unit #A615, Casper, WY 86201</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;<b>Consultant</b>&rdquo;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">OF THE SECOND PART</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><font style="text-transform: uppercase"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>eric
van lent</b></font>, an individual</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;<b>CAO</b>&rdquo;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">OF THE THIRD PART</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>WHEREAS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(A)&nbsp;the
Company is a clinical stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain,
inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. In September 2024, the Company
completed the acquisition of certain source code and intellectual property relating to an online blockchain casino, and moving forward,
will focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development
stage therapeutic product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(B)&nbsp;the
Consultant is wholly-owned and controlled by the CAO;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(C)&nbsp;the
Company and the Consultant have mutually agreed to evidence the terms of the engagement of the services of the Consultant by the Company
by this Agreement which is to supersede all prior discussions and negotiation between the parties, whether written or oral; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(D)&nbsp;the
Consultant will direct the CAO to provide the services of Chief Accounting Officer to the Company (on an interim basis) throughout the
term in order to fulfil its obligations hereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>WITNESSETH</b> that the parties mutually agree as follows:</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
1<br >
<br >
INTERPRETATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">`</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interpretation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.1&nbsp;For
all purposes of this Agreement, except as otherwise expressly provided or unless the context otherwise requires,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)&nbsp;this
&ldquo;Agreement&rdquo; means this executive consulting agreement as may from time to time be supplemented or amended by one or more agreements
entered into pursuant to the applicable provisions hereof,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)&nbsp;&ldquo;Parties&rdquo;
means the Company, the Consultant and the CAO,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)&nbsp;the
words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; or similar terms refer to this Agreement as a whole and not
to any particular paragraph, subparagraph or other subdivision of this Agreement,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)&nbsp;all
dollar amounts in this Agreement are expressed in American dollars,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)&nbsp;a
reference to an entity includes any entity that is a successor to such entity,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)&nbsp;the
headings of this Agreement are for convenience only and are not intended as a guide to interpretation of this Agreement or any portion
hereof,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)&nbsp;a
reference to a statute includes all regulations made pursuant thereto, all amendments to the statute or regulations in force from time
to time, and any statute or regulation which supplements or supersedes such statute or regulations, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)&nbsp;the
&ldquo;Board&rdquo; means the board of directors of the Company as from time to time constituted.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Engagement&#9;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.2&nbsp;The
Company hereby engages the Consultant and the Consultant hereby agrees to provide consulting services to the Company upon and subject
to the terms and conditions of this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.3&nbsp;Concurrently
with the Consultant&rsquo;s performance of the Services (as defined below), the Company acknowledges that the CAO may have other business
involvements, business interests and sources of business income, including from parties with which the Company may or may not have a relationship.
The CAO is permitted to undertake such activities and retain all compensation received from these activities provided that such activities
do not prevent, inhibit or impair the Consultant and the CAO from meeting their obligations under this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.4&nbsp;The
Consultant and the CAO hereby promises to perform and discharge faithfully the services which may be requested from the Consultant and
CAO from time to time by the Company and duly authorized representatives of the Company, including the Interim CEO and/or Board of Directors
(the &ldquo;Services&rdquo;), as more fully described in Appendix A hereto. The Consultant and CAO shall provide the Services required
hereunder in a diligent and professional manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.5&nbsp;All
services provided by the Consultant and CAO hereunder shall be in full compliance with all applicable laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.6&nbsp;At
all times that the Company is subject to reporting obligations with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), (a) CAO
shall use his best efforts to maintain the Company&rsquo;s compliance with all rules and regulations of the SEC and reporting requirements
for publicly traded companies under the Securities Exchange Act of 1934, as amended; and (b) CAO shall comply, and cause the Company to
comply, with the then-current good corporate governance standards and practices as prescribed by the SEC, any exchange on which the Company&rsquo;s
capital stock or other securities may be traded and any other applicable governmental entity, agency or organization.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Term</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.7&nbsp;This
Agreement will come into effect on January 30, 2025 and this Agreement and the Services will continue until July 30, 2025, unless otherwise
terminated pursuant to the terms under Part 4 (the &ldquo;Term&rdquo;).</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.8&nbsp;The
CAO will act under the title of &ldquo;Chief Accounting Officer&rdquo; of the Company, or such other titles or position as advised by
the Board, and will report to the Interim CEO of the Company. The CAO will receive all remuneration and other benefits of such offices
only through the Consultant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Responsibilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.9&nbsp;The
CAO&rsquo;s responsibilities will be those typically handled by the Chief Accounting Officer of a public reporting company of similar
size, and in a similar situation to the Company, as more fully described in Appendix A hereto.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Responsibilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">1.10&nbsp;During
the term of this Agreement, the CAO will</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)&nbsp;diligently
perform the Services arising under this Agreement to the best of his skill and ability, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)&nbsp;attend
to duties at the specific times and days as reasonably directed by the Company, excepting absence due to sickness and other authorized
absences as set out in this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
2<br >
<br >
COMPENSATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fees</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.1&nbsp;The
Company will pay the Consultant a monthly consulting fee of $8,000 for an average of ten hours of work per week (the &ldquo;Working Hours&rdquo;),
with each installment payable monthly in arrears (no later than 15 days after the Company has received an invoice from the Consultant),
in respect of the Services (the &ldquo;Fee&rdquo;). No deductions will be made on account of income taxes or employment insurance. All
payments made pursuant to this Agreement will be made to the Consultant. Any hours in excess of the Working Hours (evaluated on a monthly
basis) will be compensated at a rate of $200/hour (subject to receipt of appropriate documentation from the Consultant detailing the utilization
of these hours), only if preapproved in writing by the Company.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenses and Fees</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.2&nbsp;The
Company will promptly reimburse any reasonable, pre-approved out-of-pocket expenses of the Consultant or the CAO upon presentation of
appropriate vouchers and invoices, including but not limited to travel, lodging and business entertainment expenses, pursuant to the Company&rsquo;s
reimbursement policies in effect from time to time.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Independent Contractor</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.3&nbsp;The
Consultant&rsquo;s relationship with the Company shall be that of an independent contractor and not that of an employee. Accordingly,
the Consultant, as well as the CAO, will not be eligible for any employee benefits, other than as specifically provided for herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.4&nbsp;It
is the express intention of the Company and Consultant and CAO that Consultant perform the Services as an independent contractor to the
Company. Nothing in this Agreement shall in any way be construed to constitute Consultant or CAO as an agent or employee of the Company.
Consultant and CAO acknowledge and agree that Consultant and CAO are obligated to report as income all compensation received by Consultant
and CAO pursuant to this Agreement. Consultant and CAO agree to and acknowledge the obligation to pay all self-employment and other taxes
on such income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.5&nbsp;The
Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration provided
to Consultant under the terms of this Agreement. Consultant agrees and understands that it is responsible for payment, if any, of local,
state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments
thereon. Consultant agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from
and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other legal expenses, arising
from or in connection with (i) any obligation imposed on the Company to pay withholding taxes or similar items, or (ii) any determination
by a court or agency that the Consultant is not an independent contractor pursuant to this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
3<br >
<br >
THE CONSULTANT&rsquo;s and THE CAO&rsquo;s ADDITIONAL COVENANTS and representations</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential Information</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.1&nbsp;The
Consultant and the CAO acknowledge that in the course of performing the Services the Consultant and the CAO will have access to and be
entrusted with confidential information and trade secrets of the Company (collectively the &ldquo;Confidential Information&rdquo;) relating
to the business affairs, customers, suppliers, technology, proprietary rights, patents, research, plans, research data, marketing techniques,
manufacturing methods, procedures and techniques, industrial designs, inventions, improvements, discoveries and routines concerning the
Company, its business and those of its affiliates and of its customers and their particular business requirements, and that the disclosure
of any of such Confidential Information to competitors of the Company or the general public may be highly detrimental to the interests
of the Company or its affiliates, as the case may be, and the Consultant and the CAO each agree to maintain the utmost confidentiality
respecting the Confidential Information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Consultant and the CAO further acknowledge
that in the course of performing the Services they might, from time to time, be a representative of the Company in negotiations and discussions
with other parties and as such will be significantly responsible for maintaining or enhancing the goodwill of the Company and its affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Consultant and the CAO further acknowledge
that the right to maintain the confidentiality of the Confidential Information and the right to preserve the Company&rsquo;s goodwill
are proprietary rights which the Company is entitled to protect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Consultant and CAO agree that it/he
shall surrender to the Company and/or destroy all documents and materials in its/his possession or control which contain Confidential
Information and which are the property of the Company upon the termination of this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Disclosure</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.2&nbsp;The
Consultant and the CAO will not, during the term of this Agreement or at any time thereafter, disclose any of the Confidential Information
to any person, nor will the Consultant and the CAO use the Confidential Information for any purpose other than to complete the Services,
nor will either disclose or use for any purpose other than in the best interests of the Company or its affiliates the private affairs
of the Company or its affiliates or any other confidential or proprietary information which it might acquire during the course of performing
the Services, except:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(a)&nbsp;with
the prior written authorization of the Board,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(b)&nbsp;as
required to carry out the purposes of this Agreement,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(c)&nbsp;as
otherwise permitted under this Agreement, or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)&nbsp;where
the Confidential Information is in or comes into the public domain through no act or omission of the Consultant and/or the CAO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.3&nbsp;Notwithstanding
any other term of this Agreement (including this Part 3, (a) the Consultant and CAO may respond to a lawful and valid subpoena or other
legal process relating to the Company or its business or operations; provided that the Consultant and/or CAO shall: (i) give the Company
the earliest possible notice thereof; (ii) as far in advance of the return date as possible, at the Company&rsquo;s sole cost and expense,
make available to the Company and its counsel the documents and other information sought; and (iii) at the Company&rsquo;s sole cost and
expense, assist such counsel in resisting or otherwise responding to such process, and (b) the Consultant&rsquo;s and CAO&rsquo;s reporting
of possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules
promulgated under Section 21F of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or any other whistleblower
protection provisions of state or federal law or regulation shall not violate or constitute a breach of this Agreement. Nothing contained
in this Agreement (or any exhibit hereto) shall be construed to prevent the Consultant or CAO from reporting any act or failure to act
to the Securities and Exchange Commission or other governmental body or prevent the Consultant from obtaining a fee as a &ldquo;whistleblower&rdquo;
under Rule 21F-17(a) under the Exchange Act or other rules or regulations implemented under the Dodd-Frank Wall Street Reform Act and
Consumer Protection Act.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Competition &amp; Notice of Conflict</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.4&nbsp;Consultant
and CAO certify that neither have any outstanding agreement or obligation that conflicts with any of the provisions of this Agreement
or that would preclude Consultant and CAO from complying with the provisions of this Agreement. Consultant and CAO further certifies that
Consultant and CAO will not enter into any such conflicting agreement during the Term of this Agreement. Prompt disclosure is required
by Consultant and CAO if they undertake any activity which may conflict with any of the provisions of this Agreement, the Services, or
be adverse to the Company&rsquo;s interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.5&nbsp;If
the Board, acting reasonably, determines that the Consultant or the CAO is engaging in an activity which it deems to be a conflicting
activity, then the Company will so advise the Consultant or the CAO, as applicable, in writing and the Consultant or the CAO, as applicable,
will, as soon as possible in order to minimize any injury to the Company and in any event no longer than 10 days, or such longer period
as the Company and the Consultant or the CAO may agree upon, after receipt of notice,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(a)&nbsp;discontinue
the activity, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)&nbsp;certify
in writing to the Company that it has discontinued the conflicting activity including where appropriate by sale or other disposition or
by transfer of all such interests, except a beneficial interest, into a &ldquo;blind trust&rdquo; or other fiduciary arrangement over
which the Consultant and/or the CAO has no control, direction or discretion; or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">advise the Company that it disputes
the conflict and the matter will be referred to mediation or arbitration as set out under Part 5.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company&rsquo;s Proprietary Rights</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.6&nbsp;Notwithstanding
anything else in this Agreement, it is expressly acknowledged and understood by the Consultant and the CAO that all of the work product
of the Consultant and the CAO while performing the Services pursuant to the terms hereof will belong to the Company absolutely, and notwithstanding
the generality of the foregoing, all patents, inventions, improvements, notes, documents, correspondence, produced by the Consultant and
the CAO while performing the Services will be the exclusive property of the Company. The Consultant and the CAO further agree to execute
without delay or further consideration any patent assignments, conveyances, other documents and assurances as may be necessary to effect
this provision.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Special Remedies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.7&nbsp;The
Consultant and the CAO acknowledge his obligations under this Part 3 are of a special character and that in the event of any conduct by
the Consultant and the CAO in violation of this Agreement or any of these obligations, the Company may sustain irreparable injury for
which monetary damages will not provide an adequate remedy. Accordingly, the Consultant and the CAO agree that in addition to other remedies
and damages available to the Company at law or otherwise and if the Company so elects, the Company is entitled:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)&nbsp;to
institute and prosecute proceedings either at law or in equity in any court of competent jurisdiction, against the Consultant and/or the
CAO: (i) to obtain damages for the conduct, (ii) to enforce specific performance, (iii) to enjoin the Consultant, the CAO, any principal,
partner, agent, servant, employer and employee of the Consultant, and any other person acting for, on behalf of or in conjunction with
the Consultant from the conduct, or (iv) to obtain any other relief or any combination of the foregoing which the Company may elect to
pursue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.8&nbsp;If
any restriction as to time, area, capacity or activity imposed on the Consultant and the CAO by this Agreement is finally determined by
a Court of competent jurisdiction to be unenforceable (the &ldquo;Offending Restriction&rdquo;), the Consultant and the CAO agree that
upon written notice from the Company specifying for inclusion in this Agreement a lesser time or area, fewer capacities or an activity
of lesser scope than now contained in this Agreement (the &ldquo;Lesser Restriction&rdquo;), this Agreement will be deemed to be amended
by the substitution of the Lesser Restriction for the Offending Restriction insofar as is lawfully enforceable.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Consultant&rsquo;s Representations</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.9&nbsp;The
Consultant and the CAO hereby confirm to the Company that the information about the Consultant and the CAO contained in the written resum&eacute;
previously provided to the Company is materially accurate and omits nothing which would render any information contained therein misleading.
The Consultant and the CAO consent to the Company making such background checks about the Consultant and the CAO as it deems necessary.
The Consultant and the CAO further represent that this Agreement does not conflict with any agreement, arrangement or other legal obligation
to any previous employer or other person to which any duty or obligation is owed.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
4<br >
<br >
TERMINATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Termination</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.1&nbsp;Prior
to the end of the Term, subject to Section 4.2 and Section 4.3, this Agreement may be terminated on the effective termination date as
set out in any agreement between the Company and the Consultant and the CAO for voluntary termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.2&nbsp;The
Company shall have the right to terminate this Agreement at any time, provided that if the Company terminates by way of notice prior to
completion the Term:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;then
the Company will pay the Consultant $10,000, which the Consultant will accept as full compensation for the termination and neither the
Consultant nor the CAO need perform the Services during the notice period.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Amounts Due</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.3&nbsp;Any
amount due to Consultant hereunder under Section 4.2 or 4.3, shall be paid to Consultant within 60 days of the date of termination of
this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Termination for Just Cause and Other Events of Early Termination</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.4&nbsp;Despite
any other term of this Agreement to the contrary, this Agreement may be terminated by the Company without notice upon:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)&nbsp;the
death or physical or mental incapacity of the CAO and as a result of which the CAO is unable to perform the Services for a period in excess
of 30 days;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)&nbsp;in
the event the CAO or a related party to the CAO ceases to own or control 100% of the shares of the Consultant;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)&nbsp;the
receipt by the Consultant and the CAO of written notice from the Board terminating this Agreement for just cause where &ldquo;just cause&rdquo;
means any of the following events:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any material or persistent breach by the Consultant or the CAO of the terms of this Agreement;</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conviction of the Consultant or the CAO of a felony offence, or the equivalent in a non-American jurisdiction, or of any crime involving moral turpitude, fraud or misrepresentation, or misappropriation of money or property of the Company or any affiliate of the Company,</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a wilful failure or refusal by the Consultant or the CAO to satisfy its respective obligations to the Company under this Agreement including without limitation, specific lawful directives, reasonably consistent with this Agreement, or requests of the Board,</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any negligent or wilful conduct or omissions of the Consultant or the CAO that directly results in substantial loss or injury to the Company,</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fraud or embezzlement of funds or property, or misappropriation involving the Company&rsquo;s assets, business, customers, suppliers, or employees,</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any failure to comply with any of the Company&rsquo;s written policies and procedures, including, but not limited to, the Company&rsquo;s Corporate Code of Ethics and Insider Trading Policy,</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">however, no termination is deemed to be for just cause under this Agreement, except for termination for a conviction under the second subsection of Section 4.5(c), or an act constituting just cause which has already occurred and which is ascertained to have caused the Company a financial loss or loss of goodwill, unless the Board first gives written notice to the Consultant and the CAO, as applicable, advising of the acts or omissions that constitute failure or refusal to perform its obligations and that failure or refusal continues after the Consultant and the CAO, as applicable, has had thirty (30) days to correct the acts or omissions as set out in the notice.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effect on Termination under Section 4.4</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.5&nbsp;If
the Company terminates this Agreement pursuant to Section 4.4, then the Consultant is not entitled to receive and the Company will not
pay any fee, damages or other sums as a consequence of the termination (including, but not limited to any fees due pursuant to Section
2.2 or 4.2(a)), except for Fees and unpaid and reimbursable expenses accrued but unpaid prior to the effective termination date and the
Consultant will cause the CAO to resign from any office with the Company or an affiliate which the Company cannot by itself lawfully terminate.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Return of Property</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.6&nbsp;On
the effective termination date, the Consultant and the CAO will deliver to the Company, in a reasonable state of repair, all property
including without limitation, all copies, extracts and summaries, whether in written, digital, magnetic or electronic form, of documents
and information of the Company in the possession or under the control or direction of the Consultant and the CAO as at the termination
date.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Resignation of Director and Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.7&nbsp;Upon
termination hereof the CAO will immediately resign as an officer and, if applicable, director of the Company and of any subsidiaries or
affiliates, and of any other entity where he has been appointed or nominated by the Company or the Consultant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
5<br >
<br >
RESOLUTION OF DISPUTES</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mediation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">5.1&nbsp;The
parties will, in good faith, use their best efforts to resolve any dispute arising under or in connection with this Agreement among themselves.
If the parties are unable to resolve such a dispute, then before recourse to arbitration, except for a matter that would justify the granting
of a preliminary injunction, the parties will jointly refer the matter to a mutually acceptable third party (&ldquo;Mediator&rdquo;) to
mediate the matter in dispute between the parties upon the following terms and otherwise upon terms in accordance with rules or procedures
and evidence then acceptable to the parties (the &ldquo;Mediation&rdquo;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(a)&nbsp;the
decision of the Mediator will not be binding upon the parties;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)&nbsp;the
Mediation will be confidential and without prejudice to the respective rights of the parties in dispute;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)&nbsp;regardless
of the outcome of the Mediation, no party will be obligated to pay more than its own cost of participation in the Mediation and one-half
of the costs of the Mediator; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)&nbsp;at
any time after the appointment of the Mediator a party may, either in conjunction with or in the place of the Mediation, pursue all remedies
otherwise available to the party in law or in equity under this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
6<br >
<br >
GENERAL</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further Assurances</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.1&nbsp;Each
party will, at its own expense and without expense to any other party, execute and deliver the further agreements and other documents
and do the further acts and things as the other party reasonably requests to evidence, carry out or give full force and effect to the
intent of this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assignment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.2&nbsp;Neither
party may assign any right, benefit or interest in this Agreement without the prior written consent of the other party. Any purported
assignment without such consent will be void.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Severability</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.3&nbsp;If
any one or more of the provisions contained in this Agreement or the application of any of them to a person or circumstance is held by
a court to be illegal, invalid or unenforceable in respect of any jurisdiction, then to the extent so held, it is separate and severable
from this Agreement but the validity, legality and enforceability of the provision will not in any way be affected or impaired in any
other jurisdiction and the remainder of this Agreement or the application of the provision to persons or circumstances other than those
to which it is held to be invalid, illegal or unenforceable is not affected unless the severing has the effect of materially changing
the economic benefit of this Agreement to the Consultant and the CAO or the Company.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Waiver and Consent</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.4&nbsp;No
provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing
and signed by the Consultant, the CAO and on behalf of the Company by an officer specifically designated by the Board. No waiver by a
party at any time or any breach by the other party of a term of this Agreement or of performance of an obligation to be performed by the
other party under this Agreement is deemed to be a waiver of similar or dissimilar terms or obligations at the same, any prior or subsequent
time.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notice</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.5&nbsp;A
notice, demand, request, statement or other evidence required or permitted to be given under this Agreement (a &ldquo;notice&rdquo;) must
be written. It will be sufficiently given if delivered to the address of a party set out on Page 1 and if</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)&nbsp;delivered
in person to the Consultant or the CAO either by certified mail or courier so that a delivery receipt is obtained, or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)&nbsp;delivered
to the Company or the Board, as the case may be, either by certified mail or courier so that a delivery receipt is obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time, a party may give notice to the other
party of a change of address and after the giving of the notice, the address specified in the notice will be considered to be the address
of the party for the purpose of this paragraph.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice delivered or sent in accordance with
this paragraph will be deemed to have been given and received</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)&nbsp;if delivered,
then on the day of delivery,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;if
mailed, on the earlier of the day of receipt and the 7th business day after the day of mailing, or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;if
sent by telex, telegram, facsimile, email, on the first business day following the transmittal date; however,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;if
a notice is sent by mail and mail service is interrupted between the point of mailing and the destination by strike, slowdown, force majeure
or other cause within three (3) days before or after the time of mailing, the notice will not be deemed to be received until actually
received, and the party sending the notice will use any other service which has not been so interrupted or will deliver the notice in
order to ensure prompt receipt.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Binding Effect</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.6&nbsp;This
Agreement will enure to the benefit of and be binding upon the parties hereto and their successors. This Agreement is non-assignable.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Governing Law</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.7&nbsp;This
Agreement will be interpreted under and is governed by the laws of the State of Delaware and the federal laws of the United States as
applicable and, except for matters which cannot properly or lawfully be resolved by mediation pursuant to Section 5.1, the courts of the
State of Delaware will have exclusive jurisdiction to entertain any action arising under this Agreement and the parties hereby attorn
to the jurisdiction of those courts.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Time of Essence</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.8&nbsp;Time
is of the essence in the performance of each obligation under this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Counterparts</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.9&nbsp;This
Agreement and any other written agreement delivered pursuant to this Agreement may be executed in any number of counterparts with the
same effect as if all parties to this Agreement or such other written agreement had signed the same document and all counterparts will
be construed together and will constitute one and the same instrument.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Entire Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.10&nbsp;This
Agreement constitutes the entire agreement between the parties in respect of the Services and supersedes and replaces all prior negotiations,
written or oral understandings or agreements made between the parties.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Survival of Terms</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.11&nbsp;The
provisions of Sections 2.2, 2.3, 2.5, 3.1 to 3.7, 3.8, 4.3, 4.4, 5.1, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, and 6.10 and this Section
6.11, will survive the termination of this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF</b> the parties hereto have
executed this Agreement effective as of the day and year first above-written.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp; &nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><b>180 LIFE SCIENCES CORP.</b> <b>&nbsp;</b></td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:&#9;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 37%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <u style="text-decoration: none">Blair Jordan,
Chief Executive Officer</u></font></td>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 55%">) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">Authorized Signatory</td>
    <td>&nbsp;</td>
    <td>) </td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp; &nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><b>EVL CONSULTING, LLC.</b> <b>&nbsp;</b></td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:&#9;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <u style="text-decoration: none">Eric Van Lent</u>&#9;</font></td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">Eric Van Lent</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><b>ERIC VAN LENT</b> <b>&nbsp;</b></td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <u style="text-decoration: none">Eric Van Lent&#9;</u></font></td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>) &nbsp;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Appendix A &ndash; Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial Reporting and Compliance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Oversee
                                            the preparation of accurate, timely financial statements in compliance with GAAP standards,
                                            including but not limited to supervising external accountants, and working closely with auditors,
                                            legal counsel and other external parties</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Ensure adherence to all SEC reporting requirements, including filing of Forms 10-Q, 10-K, and 8-K.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Monitor compliance with Nasdaq listing standards and provide timely updates to the board on regulatory
changes.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Internal Controls and Risk Management</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Design, implement, and maintain a robust internal control framework to mitigate financial and operational
risks; such control framework should be applicable to the Company&rsquo;s current state of development, and dynamic (i.e., expandable)
as the Company grows.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Conduct regular audits and reviews to ensure controls are effective and aligned with regulatory standards
(e.g., SOX compliance).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Collaborate with internal accountants and external auditors to resolve issues and maintain transparency.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Budgeting and Forecasting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Lead the development of annual budgets, forecasts, and long-term financial plans when required by the
Company.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Analyze financial performance, variances, and trends to provide actionable insights to the executive team.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Assist in identifying cost-saving opportunities and efficiency improvements.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Strategic Leadership</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">As needed, serve as a key advisor to the CEO and board on financial strategies and risks.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Provide insights on mergers, acquisitions, and other strategic transactions.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Support investor relations by preparing financial information for use by the CEO and board when speaking
to external investors and/or investment banks</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax and Treasury Management</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Manage tax compliance and strategy, including federal, state, and international tax obligations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Oversee cash flow management and treasury operations to ensure liquidity and optimal capital structure,
including primary responsibilities for AP/AR (mostly AP) and interfacing with contract accountants and external counterparties such as
commercial banks</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Evaluate and implement financial systems and tools to streamline accounting and reporting processes.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stakeholder Collaboration</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Work closely with legal, compliance, and operations teams to align financial policies with business objectives.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Serve as the primary contact for auditors, tax advisors, and regulatory authorities.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Partner with IT to ensure financial systems meet the company's evolving needs.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Special Projects and Ad-Hoc Analysis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Lead special financial projects, including system implementations and process redesigns if required through
the Company&rsquo;s growth.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Conduct scenario analyses and provide insights to guide decision-making during economic uncertainties
or market changes</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Active participation in M&amp;A due diligence, financial analysis and financial modelling</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea023175801ex10-2_180life.htm
<DESCRIPTION>EXECUTIVE CONSULTING AGREEMENT DATED FEBRUARY 21, 2025, BY AND BETWEEN 180 LIFE SCIENCES CORP., BLAIR JORDAN AND BLAIR JORDAN STRATEGY AND FINANCE CONSULTING INC
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 10.2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE CONSULTING AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">made this 21st day of February 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AMONG</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLAIR JORDAN STRATEGY AND FINANCE CONSULTING
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLAIR JORDAN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 92%; text-align: right"></td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 1 INTERPRETATION</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>2</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Interpretation</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Engagement</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Term</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">3</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Responsibilities</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">General Responsibilities</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 2 COMPENSATION</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>4</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Fees</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Incentive Bonus and Equity
    Grant</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Vesting of Shares</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">5</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Expenses and Fees</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Independent Contractor</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">5</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 3 THE CONSULTANT&rsquo;s
    and THE CEO&rsquo;s ADDITIONAL COVENANTS and representations</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>6</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Confidential Information</font></td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No Disclosure</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">6</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No Competition &amp; Notice
    of Conflict</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Company&rsquo;s Proprietary
    Rights</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Special Remedies</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">The Consultant&rsquo;s Representations</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 4 TERMINATION</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>9</b></font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination for Just Cause
    and Other Events of Early Termination</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Effect on Termination under
    Section 4.7</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination due to Death
    or Disability</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Return of Property</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Resignation of Director and
    Officer</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Release</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Post-Termination Non-Compete,
    Non-Solicitation.</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">13</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 5 RESOLUTION OF
    DISPUTES</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>14</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Mediation</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">14</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Part 6 GENERAL</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>14</b></font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Further Assurances</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">14</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Assignment</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">14</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Severability</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">15</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Waiver and Consent</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">15</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Notice</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">15</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Binding Effect</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">16</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Governing Law</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">16</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Time of Essence</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">16</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Counterparts</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">16</font></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Entire Agreement</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">16</font></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Survival of Terms</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">16</font></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE CONSULTING AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>THIS AGREEMENT</b> is dated February 21, 2025,
and effective as of January 1, 2025 (the &ldquo;Effective Date&rdquo;). This Agreement amends, supersedes and replaces that certain Executive
Consulting Agreement between the Company, Consultant and CEO dated May 7, 2024 (the &ldquo;Prior Agreement&rdquo;), for all purposes as
of the Effective Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AMONG:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><b>180 LIFE SCIENCES CORP.,</b> a corporation
duly incorporated under the laws of Delaware, having a place of business at 3000 El Camino Real, Bldg. 4, Suite 200 Palo Alto, CA</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;Company&rdquo;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">OF THE FIRST PART</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AND:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="text-transform: uppercase"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>BLAIR
JORDAN STRATEGY AND FINANCE CONSULTING INC., </b></font>a corporation duly incorporated under the laws of British Columbia, having offices
at 244-2035 Glenaire Drive, North Vancouver, B.C. Canada V7P 1Y2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;Consultant&rdquo;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">OF THE SECOND PART</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><font style="text-transform: uppercase"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>BLAIR
JORDAN</b></font>, an individual residing at 244-2035 Glenaire Drive, North Vancouver, B.C. Canada V7P 1Y2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &ldquo;CEO&rdquo;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">OF THE THIRD PART</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>WHEREAS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(A)&nbsp;the
Company is a Nasdaq listed company with both biotechnology assets, which are currently being reviewed for potential sale or partnership,
and a Gaming Technology Platform, which the Company currently intends to operationalize through various acquisitions and/or organic development
of relevant components;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(B)&nbsp;the
Consultant is wholly-owned and controlled by the CEO;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(C)&nbsp;the
Company and the Consultant have mutually agreed to evidence the terms of the engagement of the services of the Consultant by the Company
by this Agreement which is to supersede all prior discussions and negotiation between the parties, whether written or oral, including,
but not limited to the Prior Agreement; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(D)&nbsp;the
Consultant will direct the CEO to provide the services of Chief Executive Officer to the Company throughout the term in order to fulfill
its obligations hereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>WITNESSETH</b> that the parties mutually agree as follows:</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
1<br >
<br >
INTERPRETATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interpretation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.1&nbsp;For
all purposes of this Agreement, except as otherwise expressly provided or unless the context otherwise requires,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)&nbsp;this
&ldquo;Agreement&rdquo; means this executive consulting agreement as may from time to time be supplemented or amended by one or more agreements
entered into pursuant to the applicable provisions hereof,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;&ldquo;Parties&rdquo;
means the Company, the Consultant and the CEO,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)&nbsp;the
words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; or similar terms refer to this Agreement as a whole and not
to any particular paragraph, subparagraph or other subdivision of this Agreement,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)&nbsp;all
dollar amounts in this Agreement are expressed in American dollars,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)&nbsp;a
reference to an entity includes any entity that is a successor to such entity,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(vi)&nbsp;the
headings of this Agreement are for convenience only and are not intended as a guide to interpretation of this Agreement or any portion
hereof,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(vii)&nbsp;a
reference to a statute includes all regulations made pursuant thereto, all amendments to the statute or regulations in force from time
to time, and any statute or regulation which supplements or supersedes such statute or regulations, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(viii)&nbsp;the
&ldquo;Board&rdquo; means the board of directors of the Company as from time to time constituted.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Engagement&#9;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.2&nbsp;The
Company hereby engages the Consultant and the Consultant hereby agrees to provide consulting services to the Company upon and subject
to the terms and conditions of this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.3&nbsp;Concurrently
with the Consultant&rsquo;s performance of the Services, the Company acknowledges that the CEO may have other business involvements, business
interests and sources of business income, including from parties with which the Company may or may not have a relationship. The CEO is
permitted to undertake such activities and retain all compensation received from these activities provided that such activities do not
prevent, inhibit or impair the Consultant and the CEO from meeting their obligations under this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.4&nbsp;The
Consultant and the CEO hereby promises to perform and discharge faithfully the services which may be requested from the Consultant and
CEO from time to time by the Company and duly authorized representatives of the Company, including the Board of Directors (the &ldquo;Services&rdquo;).
The Consultant and CEO shall provide the Services required hereunder in a diligent and professional manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.5&nbsp;All
services provided by the Consultant and CEO hereunder shall be in full compliance with all applicable laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.6&nbsp;At
all times that the Company is subject to reporting obligations with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), (a) CEO
shall use his best efforts to maintain the Company&rsquo;s compliance with all rules and regulations of the SEC and reporting requirements
for publicly traded companies under the Securities Exchange Act of 1934, as amended; and (b) CEO shall comply, and cause the Company to
comply, with the then-current good corporate governance standards and practices as prescribed by the SEC, any exchange on which the Company&rsquo;s
capital stock or other securities may be traded and any other applicable governmental entity, agency or organization.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Term</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1.7 &nbsp;This
Agreement will be effective on the Effective Date. This Agreement and the Services will continue until December 31, 2026, unless otherwise
terminated pursuant to the terms under Part 4 (the &ldquo;Term&rdquo;). In the event that the Parties have not agreed to an extension
or termination of this Agreement with at least 30 days written notice at the end of the Term of this Agreement, this Agreement shall automatically
renew for successive terms of one (1) year upon the expiration of the primary term or any renewal. For the sake of clarity, either party
may terminate this Agreement prior to the 30-day written notice period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.8&nbsp;The
CEO will act under the title of &ldquo;Chief Executive Officer&rdquo; of the Company, or such other titles or position as advised by the
Board, and will report to the Board. The CEO will receive all remuneration and other benefits of such offices only through the Consultant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Responsibilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1.7&nbsp;The
CEO&rsquo;s responsibilities will be those typically handled by the Chief Executive Officer of a public reporting company of similar size,
and in a similar situation to the Company.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Responsibilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">1.8&nbsp;During
the term of this Agreement, the CEO will</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)&nbsp;diligently
perform the Services arising under this Agreement to the best of his skill and ability, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;attend
to duties at the specific times and days as reasonably directed by the Company, excepting holidays (which will be a maximum of 20 paid
days on an annualized basis under the Agreement), absence due to sickness and other authorized absences as set out in this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
2<br >
<br >
COMPENSATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fees</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.1&nbsp;The
Company will pay the Consultant an annual consulting fee of $240,000, to be paid in twelve, equal monthly installments, with each installment
payable monthly in arrears, in respect of the Services (the &ldquo;Fee&rdquo;). No deductions from source will be made on account of income
taxes or employment insurance. All payments made pursuant to this Agreement will be made to the Consultant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incentive Bonus and Equity Grant</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">2.2&nbsp;The
Company may pay the Consultant or the CEO, an incentive bonus of up to 100% of the Fee (the &ldquo;Incentive Bonus&rdquo;) in the form
of cash or equity to be determined solely by the Compensation Committee in consultation with the CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2.3&nbsp;Additional
bonus payments in 2025, if any, and subsequent bonus payments in 2026 from the Company to the Consultant or CEO under this Agreement will
be based on criteria to be determined by the Compensation Committee of the Board and communicated to the Consultant and the CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2.4&nbsp;Notwithstanding
anything else herein, nothing herein shall prohibit the Board or the Compensation Committee from paying bonuses to the Consultant or CEO
from time to time in cash or equity, in their sole discretion. Additionally, any bonus earned herein shall be paid by March 15<sup>th</sup>
of the year following the date it is earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.5&nbsp;The
CEO shall be granted 160,000 shares of restricted common stock (the &ldquo;<u>Shares</u>&rdquo;), subject to the following vesting schedule,
subject to approval of the Board of Directors and the Compensation Committee of the Board of Directors, under the Company&rsquo;s Third
Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan, with such Shares to be evidenced and documented by the entry
by the Company and the CEO into a Notice of Restricted Stock Grant and Restricted Stock Grant Agreement (collectively, the &ldquo;Equity
Grant&rdquo;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.6&nbsp;80,000
Shares to vest on January 1, 2026, subject to the CEO&rsquo;s continued service to the Company on such vesting date; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.7&nbsp;80,000
Shares to vest on December 31, 2026, subject to the CEO&rsquo;s continued service to the Company on such vesting date.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting of Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.8&nbsp;The
Shares will be subject to accelerated vesting and forfeiture as set forth in the Notice of Restricted Stock Grant and Restricted Stock
Grant Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.9&nbsp;In
the event that this Agreement is terminated by us without &ldquo;<u>cause</u>&rdquo; or by Consultant for &ldquo;<u>good reason</u>&rdquo;,
we are required to pay Consultant (i) the same payments and benefits which Consultant is entitled to receive in connection with a termination
without &ldquo;<u>cause</u>&rdquo; (as discussed below), (ii) the Equity Grant and all Options and Shares then outstanding and scheduled
to vest within one (1) year of termination will immediately vest, and (iii) the treatment of Equity Grant and all Options and Shares then
outstanding and scheduled to vest outside of one (1) year from termination will be determined solely by the Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.10&nbsp;The
Company will promptly reimburse any reasonable out-of-pocket expenses of the Consultant or the CEO upon presentation of appropriate vouchers
and invoices, including but not limited to travel, lodging and business entertainment expenses, pursuant to the Company&rsquo;s reimbursement
policies in effect from time to time (collectively, the &ldquo;Expenses&rdquo;).</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Independent Contractor</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.11&nbsp;The
Consultant&rsquo;s relationship with the Company shall be that of an independent contractor and not that of an employee. Accordingly,
the Consultant, as well as the CEO, will not be eligible for any employee benefits, other than as specifically provided for herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.12&nbsp;It
is the express intention of the Company and Consultant and CEO that Consultant perform the Services as an independent contractor to the
Company. Nothing in this Agreement shall in any way be construed to constitute Consultant or CEO as an agent or employee of the Company.
Consultant and CEO acknowledge and agree that Consultant and CEO are obligated to report as income all compensation received by Consultant
and CEO pursuant to this Agreement. Consultant and CEO agree to and acknowledge the obligation to pay all self-employment and other taxes
on such income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.13&nbsp;The
Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration provided
to Consultant under the terms of this Agreement. Consultant agrees and understands that it is responsible for payment, if any, of local,
state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments
thereon. Consultant agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from
and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other legal expenses, arising
from or in connection with (i) any obligation imposed on the Company to pay withholding taxes or similar items, or (ii) any determination
by a court or agency that the Consultant is not an independent contractor pursuant to this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
3<br >
<br >
THE CONSULTANT&rsquo;s and THE CEO&rsquo;s ADDITIONAL COVENANTS and representations</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential Information</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.1&nbsp;The
Consultant and the CEO acknowledge that in the course of performing the Services the Consultant and the CEO will have access to and be
entrusted with confidential information and trade secrets of the Company (collectively the &ldquo;Confidential Information&rdquo;) relating
to the business affairs, customers, suppliers, technology, proprietary rights, patents, research, plans, research data, marketing techniques,
manufacturing methods, procedures and techniques, industrial designs, inventions, improvements, discoveries and routines concerning the
Company, its business and those of its affiliates and of its customers and their particular business requirements, and that the disclosure
of any of such Confidential Information to competitors of the Company or the general public may be highly detrimental to the interests
of the Company or its affiliates, as the case may be, and the Consultant and the CEO each agree to maintain the utmost confidentiality
respecting the Confidential Information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Consultant and the CEO further acknowledge
that in the course of performing the Services they might, from time to time, be a representative of the Company in negotiations and discussions
with other parties and as such will be significantly responsible for maintaining or enhancing the goodwill of the Company and its affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Consultant and the CEO further acknowledge
that the right to maintain the confidentiality of the Confidential Information and the right to preserve the Company&rsquo;s goodwill
are proprietary rights which the Company is entitled to protect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Consultant and CEO agree that it/he
shall surrender to the Company and/or destroy all documents and materials in its/his possession or control which contain Confidential
Information and which are the property of the Company upon the termination of this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Disclosure</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.2&nbsp;The
Consultant and the CEO will not, during the term of this Agreement or at any time thereafter, disclose any of the Confidential Information
to any person, nor will the Consultant and the CEO use the Confidential Information for any purpose other than to complete the Services,
nor will either disclose or use for any purpose other than in the best interests of the Company or its affiliates the private affairs
of the Company or its affiliates or any other confidential or proprietary information which it might acquire during the course of performing
the Services, except:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(i)&nbsp;with
the prior written authorization of the Board,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(ii)&nbsp;as
required to carry out the purposes of this Agreement,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(iii)&nbsp;as
otherwise permitted under this Agreement, or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)&nbsp;where
the Confidential Information is in or comes into the public domain through no act or omission of the Consultant and/or the CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.3&nbsp;Notwithstanding
any other term of this Agreement (including this Part 3, (a) the Consultant and CEO may respond to a lawful and valid subpoena or other
legal process relating to the Company or its business or operations; provided that the Consultant and/or CEO shall: (i) give the Company
the earliest possible notice thereof; (ii) as far in advance of the return date as possible, at the Company&rsquo;s sole cost and expense,
make available to the Company and its counsel the documents and other information sought; and (iii) at the Company&rsquo;s sole cost and
expense, assist such counsel in resisting or otherwise responding to such process, and (b) the Consultant&rsquo;s and CEO&rsquo;s reporting
of possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules
promulgated under Section 21F of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or any other whistleblower
protection provisions of state or federal law or regulation shall not violate or constitute a breach of this Agreement. Nothing contained
in this Agreement (or any exhibit hereto) shall be construed to prevent the Consultant or CEO from reporting any act or failure to act
to the Securities and Exchange Commission or other governmental body or prevent the Consultant from obtaining a fee as a &ldquo;whistleblower&rdquo;
under Rule 21F-17(a) under the Exchange Act or other rules or regulations implemented under the Dodd-Frank Wall Street Reform Act and
Consumer Protection Act.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Competition &amp; Notice of Conflict</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.4&nbsp;Consultant
and CEO certify that neither have any outstanding agreement or obligation that conflicts with any of the provisions of this Agreement
or that would preclude Consultant and CEO from complying with the provisions of this Agreement. Consultant and CEO further certifies that
Consultant and CEO will not enter into any such conflicting agreement during the Term of this Agreement. Prompt disclosure is required
by Consultant and CEO if they undertake any activity which may conflict with any of the provisions of this Agreement, the Services, or
be adverse to the Company&rsquo;s interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.5&nbsp;If
the Board, acting reasonably, determines that the Consultant or the CEO is engaging in an activity which it deems to be a conflicting
activity, then the Company will so advise the Consultant or the CEO, as applicable, in writing and the Consultant or the CEO, as applicable,
will, as soon as possible in order to minimize any injury to the Company and in any event no longer than 10 days, or such longer period
as the Company and the Consultant or the CEO may agree upon, after receipt of notice,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(i)&nbsp;discontinue
the activity, and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;certify
in writing to the Company that it has discontinued the conflicting activity including where appropriate by sale or other disposition or
by transfer of all such interests, except a beneficial interest, into a &ldquo;blind trust&rdquo; or other fiduciary arrangement over
which the Consultant and/or the CEO has no control, direction or discretion; or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">advise the Company that it disputes
the conflict and the matter will be referred to mediation or arbitration as set out under Part 5.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company&rsquo;s Proprietary Rights</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.6&nbsp;Notwithstanding
anything else in this Agreement, it is expressly acknowledged and understood by the Consultant and the CEO that all of the work product
of the Consultant and the CEO while performing the Services pursuant to the terms hereof will belong to the Company absolutely, and notwithstanding
the generality of the foregoing, all patents, inventions, improvements, notes, documents, correspondence, produced by the Consultant and
the CEO while performing the Services will be the exclusive property of the Company. The Consultant and the CEO further agree to execute
without delay or further consideration any patent assignments, conveyances, other documents and assurances as may be necessary to effect
this provision.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Special Remedies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.7&nbsp;The
Consultant and the CEO acknowledge his obligations under this Part 3 are of a special character and that in the event of any conduct by
the Consultant and the CEO in violation of this Agreement or any of these obligations, the Company may sustain irreparable injury for
which monetary damages will not provide an adequate remedy. Accordingly, the Consultant and the CEO agree that in addition to other remedies
and damages available to the Company at law or otherwise and if the Company so elects, the Company is entitled:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)&nbsp;to
institute and prosecute proceedings either at law or in equity in any court of competent jurisdiction, against the Consultant and/or the
CEO: (i) to obtain damages for the conduct, (ii) to enforce specific performance, (iii) to enjoin the Consultant, the CEO, any principal,
partner, agent, servant, employer and employee of the Consultant, and any other person acting for, on behalf of or in conjunction with
the Consultant from the conduct, or (iv) to obtain any other relief or any combination of the foregoing which the Company may elect to
pursue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.8&nbsp;If
any restriction as to time, area, capacity or activity imposed on the Consultant and the CEO by this Agreement is finally determined by
a Court of competent jurisdiction to be unenforceable (the &ldquo;Offending Restriction&rdquo;), the Consultant and the CEO agree that
upon written notice from the Company specifying for inclusion in this Agreement a lesser time or area, fewer capacities or an activity
of lesser scope than now contained in this Agreement (the &ldquo;Lesser Restriction&rdquo;), this Agreement will be deemed to be amended
by the substitution of the Lesser Restriction for the Offending Restriction insofar as is lawfully enforceable.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Consultant&rsquo;s Representations</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">3.9&nbsp;The
Consultant and the CEO hereby confirm to the Company that the information about the Consultant and the CEO contained in the written resum&eacute;
previously provided to the Company is materially accurate and omits nothing which would render any information contained therein misleading.
The Consultant and the CEO consent to the Company making such background checks about the Consultant and the CEO as it deems necessary.
The Consultant and the CEO further represent that this Agreement does not conflict with any agreement, arrangement or other legal obligation
to any previous employer or other person to which any duty or obligation is owed.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
4<br >
<br >
TERMINATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Termination</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.1&nbsp;Prior
to the end of the Term, subject to Section 4.2 and Section 4.3, this Agreement may be terminated on the effective termination date as
set out in any agreement between the Company and the Consultant and the CEO for voluntary termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.2&nbsp;The
Consultant may terminate this Agreement: (a) for &ldquo;good reason&rdquo; (meaning, without the Consultant&rsquo;s consent, the failure
of the Company to pay any Compensation pursuant to this Agreement when due or to perform any other obligation of the Company under the
Agreement, or the introduction of a requirement to be physically present in an office that is not located in Vancouver, British Columbia);
provided, however, prior to any such termination by the Consultant for &ldquo;good reason&rdquo;, Consultant must first advise the Company
in writing (within 90 days of the occurrence of such event) and provide the Company with 30 days to cure, and such Agreement must be terminated
within 30 days after the Company&rsquo;s failure to cure; (b) for any reason without &ldquo;good reason&rdquo;; and (c) upon expiration
of the initial term of the agreement (or any renewal) upon notice as provided above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.3&nbsp;If
the Agreement is terminated by the Consultant for &ldquo;good reason&rdquo;, or by the Company without &ldquo;just cause&rdquo; (as discussed
below)(other than due to death or disability), Consultant will be paid, in lump sum on the thirtieth day following such termination, a
severance payment equal to (i)&nbsp; half of the then current annualized Fee, in the event such termination occurs during the first twelve
months of the Agreement (six months of pay at annualized Fee) and 100% of the then current annualized Fee, in the event such termination
occurs after the first twelve months of the Agreement, together with all outstanding Expenses and pro-rated Fee (through the date of termination),
any unvested portion of the Equity Grant scheduled to vest within one (1) year of termination shall vest upon such termination, and the
treatment of any unvested portion of the Equity Grant scheduled to vest outside of one (1) year of termination will be determined solely
by the Compensation Committee (collectively, the &ldquo;Extended Obligations&rdquo;); (ii) any unpaid annual cash bonus in respect of
any completed fiscal year that has ended prior to the date of such termination with such amount determined based on actual performance
during such fiscal year as determined by the compensation committee; and (iii) immediate vesting of any and all equity or equity-related
awards (does not include the Equity Grant described in section 2.5 of this Agreement) previously awarded to the Consultant that vest solely
on the service of the CEO and Consultant. Any equity awards that vest based on various performance metrics will be vested only if such
performance metrics have been met at the time of termination of service and will be determined solely by the Compensation Committee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.4&nbsp;If
the Agreement is terminated without &ldquo;good reason&rdquo; by the Consultant, the Consultant is entitled to the Accrued Liabilities
(as defined in Section 4.9 below), and any equity awards or equity-related awards that are not vested as of the date of termination will
be cancelled and forfeited and any vested awards will be exercisable pursuant to their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.5&nbsp;The
Company may terminate this Agreement at any time (a) for &ldquo;just cause&rdquo; (as discussed below); or (b) for any reason other than
&ldquo;just cause&rdquo;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.6&nbsp;Any
amount due to Consultant hereunder under Section 4.3 or 4.4 shall be paid to Consultant within 15 days of the date of termination of this
Agreement and any amount due to Consultant hereunder under Section 4.3 shall be paid to Consultant within 30 days of the termination of
this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Termination for Just Cause and Other Events of Early Termination</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.7&nbsp;Despite
any other term of this Agreement to the contrary, this Agreement may be terminated by the Company without notice upon:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)&nbsp;the
death or physical or mental incapacity of the CEO and as a result of which the CEO is unable to perform the Services for a period in excess
of 60 days;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;in
the event the CEO or a related party to the CEO ceases to own or control 100% of the shares of the Consultant;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)&nbsp;the
receipt by the Consultant and the CEO of written notice from the Board terminating this Agreement for just cause where &ldquo;just cause&rdquo;
means any of the following events:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">i.</td><td style="text-align: justify">any material or persistent breach by the Consultant or the CEO of the terms of this Agreement;</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">ii.</td><td style="text-align: justify">the conviction of the Consultant or the CEO of a felony offence, or the equivalent in a non-American jurisdiction,
or of any crime involving moral turpitude, fraud or misrepresentation, or misappropriation of money or property of the Company or any
affiliate of the Company,</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">iii.</td><td style="text-align: justify">a wilful failure or refusal by the Consultant or the CEO to satisfy its respective obligations to the
Company under this Agreement including without limitation, specific lawful directives, reasonably consistent with this Agreement, or requests
of the Board,</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">iv.</td><td style="text-align: justify">any negligent or wilful conduct or omissions of the Consultant or the CEO that directly results in substantial
loss or injury to the Company,</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">v.</td><td style="text-align: justify">fraud or embezzlement of funds or property, or misappropriation involving the Company&rsquo;s assets,
business, customers, suppliers, or employees,</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">vi.</td><td style="text-align: justify">any failure to comply with any of the Company&rsquo;s written policies and procedures, including, but
not limited to, the Company&rsquo;s Corporate Code of Ethics and Insider Trading Policy,</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.25in">vii.</td><td style="text-align: justify">however, no termination is deemed to be for just cause under this Agreement, except for termination for
a conviction under the second subsection of Section 4.7(ii), or an act constituting just cause which has already occurred and which is
ascertained to have caused the Company a financial loss or loss of goodwill, unless the Board first gives written notice to the Consultant
and the CEO, as applicable, advising of the acts or omissions that constitute failure or refusal to perform its obligations and that failure
or refusal continues after the Consultant and the CEO, as applicable, has had thirty (30) days to correct the acts or omissions as set
out in the notice, if such acts or omissions are correctable.</td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effect on Termination under Section 4.7</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.8&nbsp;If
the Company terminates this Agreement pursuant to Section 4.7, then the Consultant is not entitled to receive and the Company will not
pay any fee, damages or other sums as a consequence of the termination except for the Accrued Liabilities as defined in Section 4.9 below
and the Consultant will cause the CEO to resign from any office with the Company or an affiliate which the Company cannot by itself lawfully
terminate.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Termination due to Death or Disability</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.9&nbsp;If
this Agreement is terminated due to the CEO&rsquo;s death or disability pursuant to Section 4.7(i) above, the Consultant, or the CEO&rsquo;s
estate or his beneficiaries, as the case may be, will be entitled to receive (i) any accrued but unpaid Fee through the date of termination,
any unpaid or unreimbursed expenses incurred in accordance with the terms of the Agreement, (collectively, the &ldquo;Accrued Liabilities&rdquo;);
(ii) any unpaid annual cash bonus in respect of any completed fiscal year that has ended prior to the date of such termination, with such
amount determined based on actual performance during such fiscal year as determined by the Company&rsquo;s Compensation Committee on the
sixtieth day following termination; (iii) a lump sum payment of any non-discretionary annual cash bonus that would have been payable based
on actual performance with respect to the year of termination in the absence of the CEO&rsquo;s death or disability, pro-rated for the
period that the CEO worked prior to his death or disability, and payable at the same time as the bonus would have been paid in the absence
of the CEO&rsquo;s death or disability; and (iv) immediate vesting of any and all equity or equity-related awards previously awarded to
the Consultant, irrespective of the type of award.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Return of Property</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.10&nbsp;On
the effective termination date, the Consultant and the CEO will deliver to the Company, in a reasonable state of repair, all property
including without limitation, all copies, extracts and summaries, whether in written, digital, magnetic or electronic form, of documents
and information of the Company in the possession or under the control or direction of the Consultant and the CEO as at the termination
date.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Resignation of Director and Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.11&nbsp;Upon
termination hereof the CEO will immediately resign as an officer and, if applicable, director of the Company and of any subsidiaries or
affiliates, and of any other entity where he has been appointed or nominated by the Company or the Consultant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Release</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">4.12&nbsp;Notwithstanding
any provision herein to the contrary, and as a condition precedent to payment of any amount or provision of any benefit pursuant to Section
4 (other than payment of any Accrued Obligations) (the &ldquo;Severance Benefits&rdquo;), Consultant and CEO or CEO&rsquo;s estate, as
applicable, shall execute and shall not rescind, a release in favor of the Company and all related companies, individuals, and entities,
in a form satisfactory to the Company, and any revocation period applicable to such release must have expired as of the sixtieth (60<sup>th</sup>)
day following Consultant&rsquo;s and/or CEO&rsquo;s termination of engagement If Consultant and CEO (or CEO&rsquo;s estate, as applicable)
fail to execute the release in such a timely manner so as to permit any revocation period to expire prior to the end of such sixty (60)
day period, or timely revoke their acceptance of such release following its execution, Consultant and/or CEO shall not be entitled to
any of the applicable Severance Benefits. Further, to the extent that (i) such termination of consultancy occurs within sixty (60) days
of the end of any calendar year, and (ii) any of the Severance Benefits constitutes &ldquo;nonqualified deferred compensation&rdquo; for
purposes of Section 409A, any payment of any amount or provision of any benefit otherwise scheduled to occur prior to the sixtieth (60<sup>th</sup>)
day following the date of Consultant&rsquo;s and/or CEO&rsquo;s termination of consulting services hereunder, but for the condition on
executing the release as set forth herein, shall not be made prior to the first day of the second calendar year, after which any remaining
Severance Benefits shall thereafter be provided to Consultant according to the applicable schedule set forth herein.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Post-Termination Non-Compete, Non-Solicitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">4.13 &nbsp;Upon
termination of this Agreement or for any reason other than &ldquo;good reason&rdquo; by Consultant or the Company without &ldquo;just
cause&rdquo; , Consultant and CEO agree that, for a period ending six 6 months from the date of his termination, Consultant and CEO shall
not (except on behalf of the Company or with the prior written consent of the Company), directly or indirectly, (i) engage in the business
in which the Company is engaged or proposes to be engaged (the &ldquo;Company Business&rdquo;), within the Restricted Territory (as defined
below), (ii)&nbsp;interfere with the Company Business or the business of any Affiliate, or (iii) own, manage, control, participate in,
consult with, render services for or in any manner engage in or represent any business within the Restricted Territory that is competitive
with the Company Business or the business of any Affiliate thereof or any product of the Company or any Affiliate, as such business is
conducted or proposed to be conducted from and after the date of this Agreement. As used in this Agreement, the term &ldquo;Restricted
Territory&rdquo; means the United States of America. Nothing herein shall prohibit Consultant or CEO from being a passive owner of not
more than five percent (5%) of the outstanding stock of any class of a corporation that is competitive with the Company Business and which
is publicly traded, so long as Consultant has no active participation in the business of such corporation. &ldquo;Affiliate&rdquo; means
any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with,
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon termination of this Agreement or
for any reason other than by the Consultant for &ldquo;good reason&rdquo; or the Company without &ldquo;just cause&rdquo;, Consultant
and CEO agree that, for a period ending one (1) year from the date of the termination of the Agreement, Consultant and CEO shall not directly
or indirectly through another person or entity (i) induce or attempt to induce any employee or consultant of the Company or any Affiliate
of the Company to leave the employ of the Company or such Affiliate, or in any way interfere with the relationship between the Company
or any such Affiliate, on the one hand, and any employee or consultant thereof, on the other hand, (ii) hire or engage as a consultant
or otherwise any person who is or was an employee or consultant of the Company or any Affiliate thereof until six (6) months after such
individual&rsquo;s employment or consulting relationship with the Company or such Affiliate has been terminated or (iii) induce or attempt
to induce any customer, supplier, subcontractor, licensee or other business relation of the Company or any Affiliate to cease doing business
with the Company or such Affiliate, or in any way interfere with the relationship between any such customer, supplier, subcontractor,
licensee or business relation, on the one hand, and the Company or any Affiliate, on the other hand.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
5<br >
<br >
RESOLUTION OF DISPUTES</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mediation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">5.1&nbsp;The
parties will, in good faith, use their best efforts to resolve any dispute arising under or in connection with this Agreement among themselves.
If the parties are unable to resolve such a dispute, then before recourse to arbitration, except for a matter that would justify the granting
of a preliminary injunction, the parties will jointly refer the matter to a mutually acceptable third party (&ldquo;Mediator&rdquo;) to
mediate the matter in dispute between the parties upon the following terms and otherwise upon terms in accordance with rules or procedures
and evidence then acceptable to the parties (the &ldquo;Mediation&rdquo;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(i)&nbsp;the
decision of the Mediator will not be binding upon the parties;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;the
Mediation will be confidential and without prejudice to the respective rights of the parties in dispute;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)&nbsp;regardless
of the outcome of the Mediation, no party will be obligated to pay more than its own cost of participation in the Mediation and one-half
of the costs of the Mediator; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)&nbsp;at
any time after the appointment of the Mediator a party may, either in conjunction with or in the place of the Mediation, pursue all remedies
otherwise available to the party in law or in equity under this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Part
6<br >
<br >
GENERAL</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further Assurances</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.1&nbsp;Each
party will, at its own expense and without expense to any other party, execute and deliver the further agreements and other documents
and do the further acts and things as the other party reasonably requests to evidence, carry out or give full force and effect to the
intent of this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assignment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.2&nbsp;Except
as described in Section 4.8, neither party may assign any right, benefit or interest in this Agreement without the prior written consent
of the other party. Any purported assignment without such consent will be void.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Severability</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.3&nbsp;If
any one or more of the provisions contained in this Agreement or the application of any of them to a person or circumstance is held by
a court to be illegal, invalid or unenforceable in respect of any jurisdiction, then to the extent so held, it is separate and severable
from this Agreement but the validity, legality and enforceability of the provision will not in any way be affected or impaired in any
other jurisdiction and the remainder of this Agreement or the application of the provision to persons or circumstances other than those
to which it is held to be invalid, illegal or unenforceable is not affected unless the severing has the effect of materially changing
the economic benefit of this Agreement to the Consultant and the CEO or the Company.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Waiver and Consent</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.4&nbsp;No
provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing
and signed by the Consultant, the CEO and on behalf of the Company by an officer specifically designated by the Board. No waiver by a
party at any time or any breach by the other party of a term of this Agreement or of performance of an obligation to be performed by the
other party under this Agreement is deemed to be a waiver of similar or dissimilar terms or obligations at the same, any prior or subsequent
time.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notice</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.5&nbsp;A
notice, demand, request, statement or other evidence required or permitted to be given under this Agreement (a &ldquo;notice&rdquo;) must
be written. It will be sufficiently given if delivered to the address of a party set out on Page 1 and if</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)&nbsp;delivered
in person to the Consultant or the CEO either by certified mail or courier so that a delivery receipt is obtained, or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;delivered
to the Company or the Board, as the case may be, either by certified mail or courier so that a delivery receipt is obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At any time, a party may give notice
to the other party of a change of address and after the giving of the notice, the address specified in the notice will be considered to
be the address of the party for the purpose of this paragraph.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any notice delivered or sent in accordance
with this paragraph will be deemed to have been given and received:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)&nbsp;if delivered,
then on the day of delivery,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;if
mailed, on the earlier of the day of receipt and the 7th business day after the day of mailing, or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;if
sent by telex, telegram, facsimile, email, on the first business day following the transmittal date; however,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;if
a notice is sent by mail and mail service is interrupted between the point of mailing and the destination by strike, slowdown, force majeure
or other cause within three (3) days before or after the time of mailing, the notice will not be deemed to be received until actually
received, and the party sending the notice will use any other service which has not been so interrupted or will deliver the notice in
order to ensure prompt receipt.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Binding Effect</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.6&nbsp;This
Agreement will enure to the benefit of and be binding upon the parties hereto and their successors. This Agreement is non-assignable.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Governing Law</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.7&nbsp;This
Agreement will be interpreted under and is governed by the laws of the State of Delaware and the federal laws of the United States as
applicable and, except for matters which cannot properly or lawfully be resolved by mediation pursuant to Section 5.1, the courts of the
State of Delaware will have exclusive jurisdiction to entertain any action arising under this Agreement and the parties hereby attorn
to the jurisdiction of those courts.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Time of Essence</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.8&nbsp;Time
is of the essence in the performance of each obligation under this Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Counterparts</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.9&nbsp;This
Agreement and any other written agreement delivered pursuant to this Agreement may be executed in any number of counterparts with the
same effect as if all parties to this Agreement or such other written agreement had signed the same document and all counterparts will
be construed together and will constitute one and the same instrument.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Entire Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.10&nbsp;This
Agreement constitutes the entire agreement between the parties in respect of the Services and supersedes and replaces all prior negotiations,
written or oral understandings or agreements made between the parties, including, but not limited to the Prior Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.11 Clawback.
Notwithstanding any provision in this Agreement to the contrary, any portion of the payments and benefits provided under this
Agreement, as well as any other payments and benefits which the Consultant or CEO receives pursuant to a Company plan or other
arrangement, shall be subject to a clawback (a) to the extent necessary to comply with the requirements of the Dodd-Frank Wall
Street Reform and Consumer Protection Act or any Securities and Exchange Commission rule <font style="background-color: white">or
any other applicable law; and/or (b) any policy adopted by the Company and applicable generally to Consultant and CEO and other
officers of the Company, relating to the recovery of compensation granted, paid, delivered, awarded or otherwise provided to
Consultant or CEO by the Company or its subsidiaries or any of their respective affiliates, as applicable, as may be amended from
time to time</font>.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Survival of Terms</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">6.12&nbsp;The
provisions of Sections 2.1 to 2.9, 3.1 to 3.8, 4.4 to 4.13, 5.1, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.10, 6.11, and this Section 6.12,
will survive the termination of this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page left intentionally blank. Signature
page follows].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF</b> the parties hereto have
executed this Agreement effective as of the day and year first above-written.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; width: 37%"><i>/s/ Jay Goodman</i></td>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 55%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay Goodman</font></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>Chairperson of the Compensation</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>Committee</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BLAIR JORDAN STRATEGY AND </b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><b>FINANCING CONSULTING INC.</b></td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</font></td>
    <td style="border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font><p style="margin: 0; font: 12pt Arial, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            Blair Jordan</i></font></p></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-bottom: 1.5pt">Blair Jordan</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</font></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BLAIR JORDAN</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>)</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;</font></td>
    <td style="border-bottom: Black 1.5pt solid"><i>/s/ Blair Jordan</i></td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="margin: 0">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea023175801ex10-3_180life.htm
<DESCRIPTION>FORM OF NOTICE OF RESTRICTED STOCK GRANT AND RESTRICTED STOCK GRANT AGREEMENT (FEBRUARY 2025 OFFICER AND DIRECTOR GRANTS)
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 10.3&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022 OMNIBUS INCENTIVE PLAN </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>NOTICE OF RESTRICTED STOCK GRANT</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized but otherwise
undefined terms in this Notice of Restricted Stock Grant and the attached Restricted Stock Grant Agreement shall have the same defined
meanings as in the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (as amended and restated from time to time) (the &#8220;<b><u>Plan</u></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 15%; text-align: justify"><b>Grantee Name:</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"></td>
    <td style="width: 50%; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Address:</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td style="text-align: justify">&nbsp;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You have been granted shares
of restricted Common Stock (the &#8220;<b><u>Restricted Stock</u></b>&#8221; <u>or the</u> &#8220;<b><u>Shares</u></b>&#8221;) subject
to the terms and conditions of the Plan and the attached Restricted Stock Grant Agreement, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 35%; text-align: justify"><b>Date of Grant:</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"></td>
    <td style="width: 30%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Vesting Commencement Date:</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Price Per Share:</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Total Number of Shares Granted:</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Total Value of Shares Granted:</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Total Purchase Price:</b></td>
    <td style="text-align: justify"><b>$__, Issued In Consideration For Services</b></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Agreement Date:</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Vesting Schedule:</b></td>
    <td style="text-align: justify"><b>The Shares shall vest at the rate of 1/2 of such Shares on each of [&#9679;] and [&#9679;], subject to the Grantee&#8217;s continued service with the Company on such vesting dates.</b></td>
    <td>&nbsp;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: -2.5in"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022 OMNIBUS INCENTIVE PLAN </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>RESTRICTED STOCK GRANT AGREEMENT</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This&nbsp;<b>RESTRICTED STOCK
GRANT AGREEMENT&nbsp;</b>(&#8220;<b><u>Agreement</u></b>&#8221;), dated as of the Agreement Date specified on the Notice of Restricted
Stock Grant is made by and between 180 Life Sciences Corp., a Delaware corporation (the &#8220;<b><u>Company</u></b>&#8221;), and the
grantee named in the Notice of Restricted Stock Grant<b>&nbsp;</b>(the &#8220;<b><u>Grantee,</u></b>&#8221; which term as used herein
shall be deemed to include any successor to Grantee by will or by the laws of descent and distribution, unless the context shall otherwise
require).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BACKGROUND</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Plan, the
Board (or an authorized Committee thereof), approved the issuance to Grantee, effective as of the date set forth above, of an award of
the number of shares of Restricted Stock as is set forth in the attached Notice of Restricted Stock Grant (which is expressly incorporated
herein and made a part hereof, the &#8220;<b><u>Notice of Restricted Stock Grant</u></b>&#8221;)&nbsp;at the purchase price per share
of Restricted Stock (the &#8220;<b><u>Purchase Price</u></b>&#8221;), if any, set forth in the attached Notice of Restricted Stock Grant,
upon the terms and conditions hereinafter set forth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>NOW, THEREFORE</b>, in
consideration of the mutual premises and undertakings hereinafter set forth, the parties agree as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<b><u>Grant
and Purchase of Restricted Stock</u></b>. The Company hereby grants to Grantee, and Grantee hereby accepts the Restricted Stock set forth
in the Notice of Restricted Stock Grant, subject to the payment by Grantee of the total purchase price, if any, set forth in the Notice
of Restricted Stock Grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<b><u>Stockholder
Rights</u>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<u>Voting
Rights</u>. Until such time as all or any part of the Restricted Stock are forfeited to the Company under this Agreement, if ever, Grantee
(or any successor in interest)&nbsp;has the rights of a stockholder, including voting rights, with respect to the Restricted Stock subject,
however, to the transfer restrictions or any other restrictions set forth in the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<u>Dividends
and Other Distributions</u>. During the period of restriction, Participants holding Restricted Stock are entitled to all regular cash
dividends or other distributions paid with respect to all shares while they are so held. If any such dividends or distributions are paid
in shares, such shares will be subject to the same restrictions on transferability and forfeitability as the Restricted Stock with respect
to which they were paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<b><u>Vesting
of Restricted Stock</u></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
Restricted Stock are restricted and subject to forfeiture until vested. The Restricted Stock which have vested and are no longer subject
to forfeiture are referred to as &#8220;<b><u>Vested Shares.</u></b>&#8221; All Restricted Stock which have not become Vested Shares are
referred to as &#8220;<b><u>Nonvested Shares.</u></b>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;Restricted
Stock will vest and become nonforfeitable in accordance with the vesting schedule contained in the Notice of Restricted Stock Grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;Any
Nonvested Shares will automatically vest and become nonforfeitable if Grantee&#8217;s service with the Company ceases owing to the Grantee&#8217;s
death.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) &nbsp;In
the event that Grantee is an executive officer or employee of the Company at the time of termination, any Nonvested Shares will vest and
become nonforfeitable upon the termination of Grantee&#8217;s status as an executive officer of the Company, either (i) by the Company
other than for Cause (as defined below); or (ii) by the Grantee, for &#8220;<b><u>good reason</u></b>&#8221;, as defined or described
in any employment or service agreement between the Company and the Grantee, and only to the extent such employment or service agreement
provides for a &#8220;<b><u>good reason</u></b>&#8221; termination. Except as expressly set forth herein, or in any employment or service
agreement between the Company and Grantee, any Nonvested Shares will be automatically forfeited to the Company for no consideration upon
the later of (a) the termination of Grantee&#8217;s employment with the Company; and (b)&nbsp;the termination of Grantee&#8217;s status
as an executive officer of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;Terms
used in&nbsp;<u>Section 3</u>&nbsp;and&nbsp;<u>Section 4</u>&nbsp;have the following meanings:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&#8220;<b><u>Cause</u></b>&#8221;
has the meaning ascribed to such term or words of similar import in Grantee&#8217;s written employment or service contract with the Company
or its subsidiaries and, in the absence of such agreement or definition, means Grantee&#8217;s (i)&nbsp;conviction of, or plea of&nbsp;nolo
contendere&nbsp;to, a felony or crime involving moral turpitude; (ii)&nbsp;fraud on or misappropriation of any funds or property of the
Company or its subsidiaries, or any affiliate, customer or vendor; (iii)&nbsp;personal dishonesty, incompetence, willful misconduct, willful
violation of any law, rule or regulation (other than minor traffic violations or similar offenses), or breach of fiduciary duty which
involves personal profit; (iv)&nbsp;willful misconduct in connection with Grantee&#8217;s duties or willful failure to perform Grantee&#8217;s
responsibilities in the best interests of the Company or its subsidiaries; (v)&nbsp;illegal use or distribution of drugs; (vi)&nbsp;violation
of any material rule, regulation, procedure or policy of the Company or its subsidiaries, the violation of which could have a material
detriment to the Company; or (vii)&nbsp;material breach of any provision of any employment, non-disclosure, non-competition, non-solicitation
or other similar agreement executed by Grantee for the benefit of the Company or its subsidiaries, all as reasonably determined by the
Board of Directors of the Company, which determination will be conclusive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) &nbsp;Nonvested
Shares may not be sold, transferred, assigned, pledged, or otherwise disposed of, directly or indirectly, whether by operation of law
or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<b><u>Forfeiture of
Nonvested Shares</u></b>. Except as provided herein, if Grantee&#8217;s service with the Company ceases for any reason (including Disability)
other than Grantee&#8217;s death, any Nonvested Shares will be automatically forfeited to the Company for no consideration; unless the
Board (or an authorized committee thereof) provides otherwise, and provided, however, that the Board (or an authorized committee thereof)
may cause any Nonvested Shares immediately to vest and become nonforfeitable if Grantee&#8217;s service with the Company is terminated
by the Company without Cause.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<u>Legend</u>.
Each certificate representing Restricted Stock granted pursuant to the Notice of Restricted Stock Grant may bear a legend substantially
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>THE SALE OR OTHER TRANSFER OF THE SHARES
REPRESENTED BY THIS CERTIFICATE, WHETHER VOLUNTARY, INVOLUNTARY OR BY OPERATION OF LAW, IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER
AS SET FORTH IN THE 180 LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE PLAN (AS AMENDED AND RESTATED FROM TIME TO TIME) AND IN A RESTRICTED
SHARE GRANT AGREEMENT. A COPY OF SUCH PLAN AND SUCH AGREEMENT MAY BE OBTAINED FROM 180 LIFE SCIENCES CORP.</b>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<u>Escrow
of Nonvested Shares</u>. The Company has the right to retain the certificates representing Nonvested Shares in the Company&#8217;s possession
until such time as all restrictions applicable to such shares have been satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<u>Removal
of Restrictions</u>. The Participant is entitled to have the legend removed from certificates representing Vested Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<b><u>Recapitalizations,
Exchanges, Mergers, Etc.</u></b> The provisions of this Agreement apply to the full extent set forth herein with respect to any and all
shares of capital stock of the Company or successor of the Company which may be issued in respect of, in exchange for, or in substitution
for the Restricted Stock by reason of any stock dividend, split, reverse split, combination, recapitalization, reclassification, merger,
consolidation or otherwise which does not terminate this Agreement. Except as otherwise provided herein, this Agreement is not intended
to confer upon any other person except the parties hereto any rights or remedies hereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<b><u>Grantee
Representations</u></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grantee represents to the
Company the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<u>Restrictions
on Transfer</u>. Grantee acknowledges that the Restricted Stock to be issued to Grantee must be held indefinitely unless subsequently
registered and qualified under the Securities Act of 1933, as amended (the &#8220;<b><u>Securities Act</u></b>&#8221;)&nbsp;or unless
an exemption from registration and qualification is otherwise available. In addition, Grantee understands that the certificate representing
the Restricted Stock will be imprinted with a legend which prohibits the transfer of such Restricted Stock unless they are sold in a transaction
in compliance with the Securities Act or are registered and qualified or such registration and qualification are not required in the opinion
of counsel acceptable to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<u>Relationship
to the Company; Experience</u>. Grantee either has a preexisting business or personal relationship with the Company or any of its officers,
directors or controlling persons or, by reason of Grantee&#8217;s business or financial experience or the business or financial experience
of Grantee&#8217;s personal representative(s), if any, who are unaffiliated with and who are not compensated by the Company or any affiliate
or selling agent, directly or indirectly, has the capacity to protect Grantee&#8217;s own interests in connection with Grantee&#8217;s
acquisition of the Restricted Stock to be issued to Grantee hereunder. Grantee and/or Grantee&#8217;s personal representative(s)&nbsp;have
such knowledge and experience in financial, tax and business matters to enable Grantee and/or them to utilize the information made available
to Grantee and/or them in connection with the acquisition of the Restricted Stock to evaluate the merits and risks of the prospective
investment and to make an informed investment decision with respect thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<u>Grantee&#8217;s
Liquidity</u>. In reaching the decision to invest in the Restricted Stock, Grantee has carefully evaluated Grantee&#8217;s financial resources
and investment position and the risks associated with this investment, and Grantee acknowledges that Grantee is able to bear the economic
risks of the investment. Grantee (i)&nbsp;has adequate means of providing for Grantee&#8217;s current needs and possible personal contingencies,
(ii)&nbsp;has no need for liquidity in Grantee&#8217;s investment, (iii)&nbsp;is able to bear the substantial economic risks of an investment
in the Restricted Stock for an indefinite period and (iv)&nbsp;at the present time, can afford a complete loss of such investment. Grantee&#8217;s
commitment to investments which are not readily marketable is not disproportionate to Grantee&#8217;s net worth and Grantee&#8217;s investment
in the Restricted Stock will not cause Grantee&#8217;s overall commitment to become excessive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<u>Access
to Data</u>. Grantee acknowledges that during the course of this transaction and before deciding to acquire the Restricted Stock, Grantee
has been provided with financial and other written information about the Company. Grantee has been given the opportunity by the Company
to obtain any information and ask questions concerning the Company, the Restricted Stock, and Grantee&#8217;s investment that Grantee
felt necessary; and to the extent Grantee availed himself/herself of that opportunity, Grantee has received satisfactory information and
answers concerning the business and financial condition of the Company in response to all inquiries in respect thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<u>Risks</u>.
Grantee acknowledges and understands that (i)&nbsp;an investment in the Company constitutes a high risk, (ii)&nbsp;the Restricted Stock
are highly speculative, and (iii)&nbsp;there can be no assurance as to what investment return, if any, there may be. Grantee is aware
that the Company may issue additional securities in the future which could result in the dilution of Grantee&#8217;s ownership interest
in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<u>Valid
Agreement</u>. This Agreement when executed and delivered by Grantee will constitute a valid and legally binding obligation of Grantee
which is enforceable in accordance with its terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;<u>Residence</u>.
The address set forth on the Notice of Restricted Stock Grant is Grantee&#8217;s current address and accurately sets forth Grantee&#8217;s
place of residence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;<u>Tax
Consequences</u>. Grantee has reviewed with Grantee&#8217;s own tax advisors the federal, state, local and foreign tax consequences of
this investment and the transactions contemplated by this Agreement. Grantee is relying solely on such advisors and not on any statements
or representations of the Company or any of its agents. Grantee understands that Grantee (and not the Company)&nbsp;is responsible for
Grantee&#8217;s own tax liability that may arise as a result of the transactions contemplated by this Agreement. Grantee understands that
Section&nbsp;83 of the Internal Revenue Code of 1986, as amended (the &#8220;<b><u>Code</u></b>&#8221;), taxes as ordinary income the
difference between the purchase price for the Restricted Stock and the fair market value of the Restricted Stock as of the date any restrictions
on the Restricted Stock lapse. Grantee understands that Grantee may elect to be taxed at the time the Restricted Stock is purchased rather
than when and as the restrictions lapse by filing an election under Section&nbsp;83(b)&nbsp;of the Code with the Internal Revenue Service
within 30 days from the date of purchase. The form for making this election can be found at https://www.irs.gov/pub/irs-pdf/f15620.pdf.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GRANTEE ACKNOWLEDGES THAT IT IS GRANTEE&#8217;S
SOLE RESPONSIBILITY AND NOT THE COMPANY&#8217;S TO FILE TIMELY ANY ELECTION UNDER SECTION 83(b), EVEN IF GRANTEE REQUESTS THE COMPANY
OR ITS REPRESENTATIVES TO MAKE THIS FILING ON GRANTEE&#8217;S BEHALF.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<b><u>No
Employment Contract Created</u></b>. The issuance of the Restricted Stock is not to be construed as granting to Grantee any right with
respect to continuance of employment or any service with the Company or any of its subsidiaries. The right of the Company or any of its
subsidiaries to terminate at will Grantee&#8217;s employment or terminate Grantee&#8217;s service at any time (whether by dismissal, discharge
or otherwise), with or without cause, is specifically reserved, subject to any other written employment or other agreement to which the
Company and Grantee may be a party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<b><u>Tax
Withholding</u></b>. The Company has the power and the right to deduct or withhold, or require Grantee to remit to the Company, an amount
sufficient to satisfy Federal, state and local taxes (including the Grantee&#8217;s FICA obligation)&nbsp;required by law to be withheld
with respect to the grant and vesting of the Restricted Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<b><u>Interpretation</u></b>.
The Restricted Stock are being issued pursuant to the terms of the Plan, and are to be interpreted in accordance therewith. The Board
(or an authorized committee thereof)&nbsp;will interpret and construe this Agreement and the Plan, and any action, decision, interpretation
or determination made in good faith by the Board (or an authorized committee thereof)&nbsp;will be final and binding on the Company and
Grantee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<b><u>Notices</u>.</b>
All notices or other communications which are required or permitted hereunder will be in writing and sufficient if (i)&nbsp;personally
delivered or sent by telecopy, (ii)&nbsp;sent by nationally-recognized overnight courier or (iii)&nbsp;sent by registered or certified
mail, postage prepaid, return receipt requested, addressed as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;if
to the Grantee, to the address (or telecopy number)&nbsp;set forth on the Notice of Grant; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;if
to the Company, to its principal executive office as specified in any report filed by the Company with the Securities and Exchange Commission
or to such address as the Company may have specified to the Grantee in writing, Attention: Corporate Secretary;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">or to such other address as
the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such communication
will be deemed to have been given (i)&nbsp;when delivered, if personally delivered, or when telecopied, if telecopied, (ii)&nbsp;on the
first Business Day (as hereinafter defined)&nbsp;after dispatch, if sent by nationally-recognized overnight courier and (iii)&nbsp;on
the fifth Business Day following the date on which the piece of mail containing such communication is posted, if sent by mail. As used
herein, &#8220;<b><u>Business Day</u></b>&#8221; means a day that is not a Saturday, Sunday or a day on which banking institutions in
the city to which the notice or communication is to be sent are not required to be open.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<b><u>Specific
Performance</u></b>. Grantee expressly agrees that the Company will be irreparably damaged if the provisions of this Agreement and the
Plan are not specifically enforced. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Agreement or
the Plan by Grantee, the Company will, in addition to all other remedies, be entitled to a temporary or permanent injunction, without
showing any actual damage, and/or decree for specific performance, in accordance with the provisions hereof and thereof. The Board (or
an authorized committee thereof)&nbsp;has the power to determine what constitutes a breach or threatened breach of this Agreement or the
Plan. Any such determinations will be final and conclusive and binding upon Grantee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<b><u>No
Waiver</u>.</b> No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent breach
or condition, whether of like or different nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<b><u>Grantee
Undertaking</u>.</b> Grantee hereby agrees to take whatever additional actions and execute whatever additional documents the Company may
in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions
imposed on Grantee pursuant to the express provisions of this Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<b><u>Modification
of Rights</u>.</b> The rights of Grantee are subject to modification and termination in certain events as provided in this Agreement and
the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<b><u>Governing
Law</u>.</b> This Agreement is governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect
to its conflict or choice of law principles that might otherwise refer construction or interpretation of this Agreement to the substantive
law of another jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<b><u>Counterparts;
Facsimile Execution</u>.</b> This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original,
but all of which together will constitute one&nbsp;and the same instrument. Facsimile execution and delivery of this Agreement is legal,
valid and binding execution and delivery for all purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<b><u>Entire
Agreement</u>.</b> This Agreement (including the Notice of Restricted Stock Grant)&nbsp;and the Plan, constitute the entire agreement
between the parties with respect to the subject matter hereof, and supersedes all previously written or oral negotiations, commitments,
representations and agreements with respect thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<b><u>Severability</u>.</b>
In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and this Agreement
will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<b><u>No
Advice Regarding Grant</u></b>. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations
regarding your participation in the Plan, or your acquisition or sale of the Restricted Stock. You should consult with your own personal
tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;<b><u>Compliance
With Law</u></b>. You agree that the Company shall have unilateral authority to amend this Agreement without your consent to the extent
necessary to comply with securities or other laws applicable to issuance of shares of Restricted Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;<b><u>Electronic
Delivery and Participation</u></b>. The Company may, in its sole discretion, decide to deliver any documents related to current or future
participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate
in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;<b><u>Other Documents</u></b>.
You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act, which includes the document containing the Plan information specified in Section 10(a) of the Securities Act
(&#8220;<b><u>Prospectus</u></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;<b><u>WAIVER OF JURY
TRIAL</u>.</b>&nbsp;THE GRANTEE HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING
RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page Follows]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>IN WITNESS WHEREOF</b>,
the parties hereto have executed this Restricted Share Grant Agreement as of the date first written above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>180 LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"></td>
    <td style="width: 60%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GRANTEE:</b></font></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="border-bottom: Black 1.5pt solid"></td>
    <td>&nbsp;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Grant Number XX-XXXX</i></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SPOUSE&#8217;S CONSENT TO AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Required where Grantee resides in a community
property state)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that I have
read the Agreement and the Plan and that I know and understand the contents of both. I am aware that my spouse has agreed therein to the
imposition of certain forfeiture provisions and restrictions on transferability with respect to the Restricted Stock that are the subject
of the Agreement, including with respect to my community interest therein, if any, on the occurrence of certain events described in the
Agreement. I hereby consent to and approve of the provisions of the Agreement, and agree that I will abide by the Agreement and bequeath
any interest in the Restricted Stock which represents a community interest of mine to my spouse or to a trust subject to my spouse&#8217;s control
or for my spouse&#8217;s benefit or the benefit of our children if I predecease my spouse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</font></td>
    <td style="border-bottom: Black 1.5pt solid; width: 30%; text-align: justify"></td>
    <td style="width: 60%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name:</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"></td>
    <td>&nbsp;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 11</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 Omnibus Incentive Plan</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Restricted Stock Grant Agreement</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>
<p style="margin: 0">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atnf-20250215.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kk5s7xRiXhun8uNbHcsWaKNiaPtzp95KYlBuGl3fTl6ny0o16rE1ii55kQGwVgA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20250215" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20250215">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250215_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250215_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250215_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>atnf-20250215_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20250215.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250215.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250215.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>atnf-20250215_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20250215.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20250215.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>atnf-20250215_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20250215.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250215.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250215.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45843964397600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 15,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ..!55H#.?L_[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ..!55J97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ XX%5
M6O]-GK"[!   <Q0  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ..!55K@]#J)J@(  # ,   -
M      "  ?X,  !X;"]S='EL97,N>&UL4$L! A0#%     @ XX%56I>*NQS
M    $P(   L              ( !TP\  %]R96QS+RYR96QS4$L! A0#%
M  @ XX%56JK$(A8S 0  (@(   \              ( !O!   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ..!55HD'INBK0   /@!   :
M  "  1P2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ..!55IED'F2&0$  ,\#   3              "  0$3  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  $L4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0231758-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20250215.xsd</File>
    <File>atnf-20250215_def.xml</File>
    <File>atnf-20250215_lab.xml</File>
    <File>atnf-20250215_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0231758-8k_180life.htm">ea0231758-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0231758-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20250215",
   "dts": {
    "schema": {
     "local": [
      "atnf-20250215.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20250215_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20250215_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20250215_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0231758-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0231758-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0231758-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20250215",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20250215",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-25-016103-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-016103-xbrl.zip
M4$L#!!0    ( ..!55IU\ +QT ,  .H.   1    871N9BTR,#(U,#(Q-2YX
M<V2]5UMWVC@0?M]S]C^H?MWC&Y1LXT)[LLDFY>12-M"T^]0C;!ETD"57D@/9
M7]^1;1'N!=HL3_+H^^8BS8R&]OM9QM CD8H*WG%"+W 0X;%(*!]UG$]]]ZQ_
MWNTZZ/V[WW]#\&N_<EUT20E+(G0A8K?+4_$6W>&,1.B*<"*Q%O(M>L"L,!)Q
M21F1Z%QD.2.:P$9E*4(MK]$:(M?=0^\#X8F0G^Z[<[UCK7,5^?YT.O6X>,13
M(2?*BT6VG\*^QKI0<VW!+*A_^]%OJ8KGY#^N)RWUY^R>?AD7_$UQ-_P0J\_X
M^H[BGOXO/VU=_\O^*JY8,QVP$_X4B/!$_AU2VFI-_KF:/HS.*I-M%8])AA%<
M!E<=Q\17AS=M>D*._$80A/Z7VYM^B7,J8#1CE$\VP</3TU._W+70->1L*)E5
MW?3-]A K,M<,NW0'GG*E,8^7\(F>$Q;!+;_:7(+2C="3"DHM-"$K.$5B;R0>
M?=@ ?..U!1;*'6&<S\$I5L-2:;VQ!%92KP-!N IR]5-.U$9HM;5$2+1<(2R=
M&FS[9MMP&F[0=)NA99X-[B[GI/!-P&A*5$RA#$F9U(;2"AIA"TJ3D8QP?2ED
M=D%27#"(Y%N!@4%)XB"-Y8AHDZ4JQS'93ZG->,RY@,* ZJPE1I;G%#)_+@"1
MR91("D8&$ TR"ZC,G98,QC\7T&0<1)..4RT7=%JM"4DIIZ4'=4&&R#7E5YB@
M85DRV_XJ>%U3H4CRD;\KU[DD"NAE9#<@J/DU9#<WQBPNV%'49_]V,6NY/<^U
M@[9U>4]25-9S9)*HXRAJ.JI3R\:2I!T':YZZ]EJ_0M@>Y)>%& L[ZKF\H]63
MJ@U;%5C&:UK6^@TH$3F1FD)Y+#25RG6J#;VW8 89.\I!_B^,G.'AH9$#A; 7
M#/G&Z'^)6"'+#HUU.3%?*."+N9'UJ-O^<EN![]76TX; A=2(K[6R74]1]8C>
MB+A4M8-BOES+<XW(#1O0D;V92IX]/<2)YV,XS G+.\*)+0_B)OMJ&]PL3#*]
MWM?HEH=UI]&-')\PK:SD:!<6G^&?\*%4<Y 3/W[;M[GS(V;YK8Y*@E@47,NG
M0Q)AD6(_CKN-YP%JOXNP^.H2S$QUK-DCLF#=^-84J$>N<G(QD]I7^#.3"=[7
M(I[TL"S_!@2>F55Z1/;'6));D@W-K&.\-M/.OG#*X!DRS5/+PO13,X)'T&>I
M2 ;E<Y 4LHP*!KWJVXZ<42(R3'E7D\P@X12*H8).7!CTE10%3,:5.@J07<%]
MQE)BKM5 ] H9CZ$SE3ZJC^E"',L!'D;Y?X-L^U4^P/([4$L#!!0    ( ..!
M55KQ9!"5 0D  )5H   5    871N9BTR,#(U,#(Q-5]D968N>&ULU5U=<]LV
M%GWOS/X'KOHLZ\/Q;N/&[2B*U=$TB5U+3;I]\4 D)&$, 1X M*5_OP _9%+$
M)2G7ADD_V!1U+W#N.2" 2P+TAU^W&^H]8"$)9Q>=P4F_XV'F\X"PU47GSUEW
M-!M/IQU/*L0"1#G#%QW&.[_^\J\?//WSX=_=KC<AF ;GWB?N=Z=LR7_VOJ(-
M/O=^PPP+I+CXV?N&:&C.\ FA6'ACOKFG6&']15SQN7=V,CQ;>-UNC7*_819P
M\>?-=%_N6JE[>=[K/3X^GC#^@!ZYN),G/M_4*W"FD KEOK3^MI_\Q.X?*&%W
MY^;7 DGL:;Z8/-]*<M$Q]2;5/IZ><+'J#?O]0>^O+Y]G_AIO4)<PPYN/.ZF7
M*<7F-WC__GTO^C8U+5AN%X*F=9SV4CC[DO6W@=H[9(W/>O&765-24G0&M"3G
M,HKD,_>1BEI()2(/M#"?NJE9UYSJ#H;=T\')5@:=5*>(;,$IOL%+S_S50N]K
M'?S4IV2)I4]T&\61Q#UCTQMSW80UX,A[+?#RHH,46^I*AF?]X>#,5/%CSDCM
M[G53EL2TQ([7RU6/A)\BL!EG:P&"33DW4<:5KW41P@\7N!N0#6:FU7>\I*)L
MB/M2"%,];=I+;'K6 EX?][ZR;L WB!P)NNCM '%44W>#-PLC]U%P\ZZOCQ51
M>AS"R.'U<3&N1L="2WV<MDF\1"%5SVZ4J7L>LSY-&#']W6?],8<;;Y4>?G"0
M(C<%'MD]*:*,3S+&#+RN&9!"#4GIP]@R09/BH=S/@:"F-^:BR)Y,PUXBN8AB
M#V5WA="]YG'XKH>IDND9TS6^B]A,3MR:81 ;&#IH/-6',JV H@6F4;6WB;'-
MMO>VJ.=H\=2@2A G=H=HGS0?B11WTF!J7I5Q*SWW.5.ZE5S2J#;=TO'*'*3(
MEH)O*JE,:..E$62YU4 Z'A<!%GH.UW_"0KG$P45'B= 2LF.!QA1)>;6<*>[?
MC;:D3NLJNKRH;-8AM4JF//N 1%"L%K7>2I<LQ$_)X P)8K-]426*\X0J&4"&
M>25R2(IAOYU:W XLP%]*CG2$_*>]V[/UBJ*#)#M]KF3%[& T_SJYU9GIAK.H
M]FLDHH2P?V)&Z6LL9FLD\)=D:EA0Q[C7]'X%O?+S5D"+DFN!/R\(L%-[;J\&
MR/(="8&8DG-^'0I_K=/'"(D.)H.V5)HC2KBU]0.-D>?80,#.[D4&'HG]DQ5_
MZ 68Q/V</GCJWO2'VW1N.]<E6K31)EF+VW=OPWWU),P&%.+V1<:1:FI'&DQ@
M $TH6MFYS9DTFMPBTE>=,1W![B>=T ERKS*S0X#DC&4[N#X$#'86;ON*&[PB
M4HGHCN,^H/+.P^K2:!&JD8.3'K=JC!@+$;W!]UQ4B)"U; 7W!< 0Y>_<4OY'
MB(3"@N[JL'Y@W KB;9@A[L\<3U3T]$I&5-4A_]"Z%>Q;04/T_\<M_;,UIM0\
M($2L5NLOVK=" @ V),)_WTZ$RP<S4="AU==A[](Z*?+((35^<JN&3KP)#W1,
MHH8.!\:M4,"&&>+^_5MP?\F"NLPGIBWB/8NX[)F"2]HG1/J(QO@F^ISM84$F
MD()Y*^BWHW[Q>VK_2(+_821J"[ W;A']><P@^8XRX'$H1 Y::<\#63>:_E+0
M(/^.<MY+IHC:F55J7T/@;K(V.[1J--]6L"#/CA+=&%1ZZX,ILQ"OC.N\90OX
MM@ &.7>4X,; QAJ^0'3* KS]'>_*2#\P;0'K-L0@[8X2VQC9M2 ;)'8SXE=W
M+(>V+2#>"AEDWE$V&T.;H^TTT$&0)8G7L%8+ +BT0(<RY* <CM+9&.&4^5S<
M\\S][C$/]56[&_.@= @H=6R!--7X08$<Y;PQSE$0""QE\L?$-2B3Q6+> C$@
MU. #,$?Y+X1N>)P$PU9*,"R7P%'^"Z$[/4Z"TU9*<%HN@:,L.(=NK ^OQ)P_
M D_? >/VT'^ &23?:0J<8(NBN1+7@C^0>$M0E0(''NV1P08<U,)IFIRVDWBZ
M4.<JB"W;PWT6,,BYTS0Y 7;-I4+T;W)?-3NUV;>'_R)L4 5'67/2(LQM%&C9
M5<ZDT5P7D8+T.DJ-S9@S$AC!S3IKT6QR#X&"W#K*<S]S\U1GS5GI/>1#JT9S
M; 4+\NPJ735;\238/>R_;C2S>900I<_>YG DI=\%41J/64D>LN0.$O#DSVK:
M:*IAQ"#MCE+.&:?$UPRQU1<=AR"(VCDOVC6:<  NR+:C[/):8-,&S!;=:#&<
MV<\KKI9+J*>&[1O-?@5L4 5':>8!O*F4(1;':E'P:I,B=O"@+HY2SAGV0]U1
M[@;#Q=QL5 =ZH@.K1O-N!0OR["C-_,KG IFW[,QVFP6G\!8>BV&CV8;P@H0[
MRBASJ.Q4YTP:37(1*4BOHXPRO<@NM_X:L16&5W38+!M--@@8Y-Q1IOG4L:UJ
M]=6K-O75JQI]M:-,,P45+]37U]W5@I(5@G<$ECBT@GT(-R2$+:;7$"+>KV7>
MW28V$:J)/K!+8#5M-/DP8I!V5UMAPX H',0 )X0AYNMD;A\4<(>@RJO98M0!
M#^KB]#GI=TSI[XP_LAE&DC,<Q(E%V=,*P*71BE0C!^5P^N3T&Z<A4TA$2VX%
M<&U835M OPTQ2+O3AZ3)LO+]R!6_U+.,?;M'"T0H 0YJX?3AZ90I+)"OR /^
MA!1*\)9I8?=H@18EP$$MG"X\CB[4L8YGQ<O7#N0,6\!\$2](N-/UQK,-HO1C
M*'4 LK3_R1FV@/ B7I!PIRN*+S=8K'0W^)O@CVJ=;.0M(][JT (!8-R@$$Y7
M#E]NGUXL$.]J+%6A8-T&">R@(?[/'&^;'?F^66H2SPE8@ 2@ &S?: TJ8(,J
M.$J3K]0:B^RL+()F@BE;"%+EU6A%:H$'=7&:)F=?\U Z+&?L&LT] !=DVVD6
M?!TN*/$GE*/2>7_&K 5<'Z(%J7::^7Y$[$Z$]\K?70ON8VP>#,G]-5DC^:I5
M0 ODJ1\'*)S;K;A/+^Q,WN$9JNC_K&BTI3<N2OQ:(%,E?% =QZ^BDD];]G#P
M<7>#EUB8Q1MSO%4?=45WY9.K2O=&:W5<%*!DF=3[0^\@0%W]G?XN.6]^F7\,
MH\_\'U!+ P04    " #C@55:WQG8^_(+   4D   %0   &%T;F8M,C R-3 R
M,35?;&%B+GAM;,V=;V_;NA7&WP_8=^"\O;@#ZCAQU@');>]%FB87P4V3K';;
M;<50T#+M")%)@Y(3Y]N/?R19HG@D.>TEV1>M*SV'>BC^3%*R>/3FU^TJ08^$
MIS&C;P='!X<#1&C$YC%=OAU\F@S/)N=75P.49IC.<<(H>3N@;/#K+W_^$Q)_
MWOQE.$27,4GFI^@]BX97=,%^1C=X14[1;X02CC/&?T:?<;*16]AEG!".SMEJ
MG9",B!WZP*?H]<'X]0P-ASW*_4SHG/%/'Z_*<N^S;)V>CD9/3T\'E#WB)\8?
MTH.(K?H5.,EPMDG+T@ZWA_D?'?XFB>G#J?QKAE."Q/FBZ>DVC=\.Y''SPSX=
M'S"^'(T/#X]&__YP/8GNR0H/8RK/6T0&190LQ19W=')R,E)["VE#N9WQI#C&
M\:BP4Y8L]L8M^HJ3-#Y-E;UK%N%,-7OG81"HD/\;%K*AW#0\&@^/CPZVZ7Q0
MG'QU!CE+R$>R0*J:I]GS6J"4QI*$0;[MGI.%W4S"^4C&CRA9XHS,Y8%.Y(&.
M_BD/]-=\\S6>D62 I%+P =;KI%96'C1R;?:.\)C-+^C+7)O1GNR+[P[/OJ,"
MU7CG59BR#"<O,E^-=&[[AKSLC._BW)]IT<^3EYWI2N0?8CMK6M[[]-K/:R(W
M7HM/-8MDFXD!C,P+D[*(EAY8'4$-#'G99>DLJI6;R-Z<\6;=Y<BHRES@=*8*
MWJ3#)<9K<8#Q/T8DR=)BRU!N42<AW_!-CHUD16AVGN TO5U,,A8]G&WCM#B.
MJN3;00_]R*R C#SC12TPCSI.1:X814P,9.MLF.B3KL,7G*UZV<C/&>LA_I;,
MRO+U2186@(K49)RD;,,CLE<;5VO3]ZSF#E>)B) 3-D*'GR:#7Y0,L0520O15
M2O_W9K0K^B4LX8PN)""O#\='KQ4D9].;RV]B,K=B5!WH#G,UASH\$).G(]'!
M3^XQ)Q_(:D:X4;/]0EV@\Y+*2(KVB?,.U O,-MA2T9JL5VB-.7J4):"_Z3+0
M6DSP4UG*'\3;%\PYIEDZ97?BC-R+6:?R++X5E7K!S.T5[HR[%U2J9&^/V##X
MV]^PR6!1 LH86N=E:.A4KU=%]'LI_'$CZ!3/=E,3J(//15[&RII!ZP"I%-XA
M:K5EHE**T%<E^^YA\,<!(::&Y$I\[)Q+581>P&@8M<)1JL(#Q+36 HF4(J7]
ML:2D)#I8LL?1G,0:$O%AQX;XS[?W+-HHFD6)1H6:NUUP )F2K6_N\][F@"&S
MI0L)DAK'#7PF#CR7![],\-)BW]COJHFMMHHVKNT,HI%MCLQ6+C5(BGPU\WN2
M1CQ>RUNL;?6HR9PWNL5DH^TKFK 0:!J#2:AH/77L'\DR3C.N[KF7(TY+-P;H
M77?]K;;-L< J#@*:/@[!T:(:A,HH3QR=4;K!R4>R9KP-G[K,-34VDR8L54U0
MC%B,@6AH+=)B3T3\:X-Y1GCRW E%0^F:"\"JB88A"XH.NS<0D%+NEY$IQS2-
M90?6"4E3ZOQR S#;N/0P=$%Q IB#+TE*O5]2)O<D2>0S&IAV=R@VL6M:8,,F
M+TUE4,2 ]D!F5 3*0\+!YN)1SL[%-*EG92MZG_ T;+?Q4XJ#1<ATV),B%89D
MG">2*H^&=##44+JF![!J<F/(@B+&[@UD1<N1TON'Y(+.>R%2ZOP 8MBTXY&+
M H2C[JP+#:'V"<9EG$8XT5XNQ3;SYY4.K6M 0+LF) UA4*! [D!8=$#!C KQ
M"LQ_".;]<*DH_<#2L&I'I90%"(KIK0L3J?<"R?F&\YIK>,2!I:XPZ3);< +I
M@@"EPUSC>20MKX'B:02ZH%F</<LU#C<;R_-'=HDK-B!S!1/F_B!8 $R9#&@9
MDCJDA5Y:OOB5@&9R80E8'5/FE@"[R3H%=4U )%B- 33LM&J=CQ<BSD7/Q'%R
M1>=D^SMY!NO5T+EE K!9A\(0!42%W1F 12Y&2HV$W L8=SQ>8?X\B:..H:(I
M=(L&9+3.AJD*" [ &D!'KD:3JW.?(\D4;Z_F M1X$>LU>AV4@'JWL'38KC,#
MB -"I]TA0) (0O4HGR!=T8CQ-:L\[G#.-J(#?#YG<WB&TA'E%JI>5:BCU1H2
M$&!]? *8U4)?Z6=2$)-KJU4!2);@A;BS^5R<J#3_YSJFY BLOU7KEJX6NW6F
M+,* 2(+= ?SDRE?%!R1CT"T-!9KQ'E4=^X=FW!>:<=#0C%\"S?2)!0+-\1Y5
M/?8/S7%?:(Z#AN;X1="(AO?:UYR+C[=\RIYL#V>#2B_(-*U:@=G)PL.EX:T+
M%AD@YS,RQ"<F:F)UR^\X>XQI!$^9(;D78 #35FH,;7CHV UV\5-.B(LXKWV-
MGI1W?DD*F9]>IF[2WL5H37B0U(UU=BY:[1.).Y9F./EOO&Z]$+>+O>!A-6R%
MI*8,#Q6;O2Y@= P203XNK'-<Y0\:UJ5DQGYGOS;;;)4_,5=W!@&!S5$SN86^
M>Z)%KIM9,LH)!GJ$^FYGC6PQ5;9Q95\83=PTU&AA];T6&A]?9)EQ+[F[9Q1^
M0* I<=72D+FBM<W]0;0X8,IL=25#2N?I;KS,^I7:N^_*/F<CNVFG',B+'4&T
MKNFF,4P7^QVWYA<>9^+(,L_,AN:_\MB>&P1TKEJYU6;1XE91$*W?YJR1$4AK
M45WL&(L)2^(HSF*Z_" N/GF,;;6RB5P! 1LL:&@J@D !M-7(Y%(*4:%T#,$=
M)Q)"(AI"+0*4R1[Y[6)A'>W;Q*Z@Z#9<P $K@X"DTYX)BP@81I4(I$.0BO&+
MS56:;@C?"QY+B">$0/, 2 U]B#A!)CNATH$^V9J0:"/&Q^>C\6P:9XTD=':)
MLS$),%>.2,;^(-@ 3)DLJ'TR(^'1^*?9WU$1Y;CY;]B48YG0?_*\FK$$R#YE
M5;F"H,5BP8%%$@0*L"^3AAN&<BG26A_9J6IF+=4Q]KL"P&JK:/K:SB :W>:H
M\>6OM;6G+O]B&]T+4P18D&"7N>[Z;2;-[K^J"0*!%F.-BY)<B@JMCP4)NR%K
MV3T)6'J;!"P[)@'+$"<!R[Z3@*6W24!Q6)TB1/1+M[,D7F(@.6&KVC44+99-
M/BS2H%"!_8%]1AF"=C&N,UJJ%&?RE4E\I8Y_*3Y8:@GHG.6T;+-9)K6TB8)@
MI,U9(ZVE3CI7$2.I=LW%9AYG9*[-7,84TRC&29D>T79'O#O$&2T]S9?@=.C#
M8*B?R09..JS(95@&[E)=NKZ5KA_ ^$*2Y'?*GNB$X)11,M?W4FR_%+7KW3XQ
MTV&[_M ,( X"ISX.@4=G9-#P04:A(BR_$^:%I,\LV= ,<[66G-MZ)D#GEAS
M9IT80Q00*79G "&E&&FUGP7:.GM$.<G2[X($*PC)'2_7;C5MK-JV:@-BIM4@
MM(8[S_FQFQOK*$]++#/"<93%C^0]SG#N#:PO)'>]J++-M+F:TJ8-"*%6@^#Z
MR3)&IHK!!5/>4L;P<S'56K*6I\0-E?O$,0V+S=PQI20@/&R^6C+(<%1HO; P
M6>$D>;=)8TI2>" R5&Y9L%JLLU"3!,2"S1? @I*B0NN%A8L5X4LQO/W&V5-V
MG^=G!>L&J-VRT6JYSHA5&A K;?X 9HH0I&.*E+I^X-GN$HKK+(MP32U2Q]B
M9@UF&KJ0@(',-6A)2"3OM]RP#$T9^I02E-T3=)&_&KB:"5Z7X^M-(U$D%T3H
M63F=8VY#J$WL_*TCH.'&NT<:RB! ZK0'OX>DC$!%B&-J;@7#O'H=ITS(=^F!
MJQVZ0UP1U-=\P5&7/@B:>IHTF5)A]8MK%:C>B^@SFU$UN3T\Q:N)',^,+0:-
MB7%%$00CH"UH6EQ]5X"?W'F;61)'EPG#\%V6FL9QQKRF/2-9WDX0$ %-5U"*
M/"5$2NFE_=]A^L WZRQZON,L(D0^9966O577_;>>T6Z9V:M*=9IZA0;$V3Y^
M 0)W1:!*&:\J(Y;/FWF5EYCG[S7?9*D<084Q^"YX:Y#CGQ=Z5,#XD:$E(B#T
M>MB$?G"HO%'^%=+!J!+MZ?HLW64!)/-WSQ_)@G"Y[F!*MMD[<:"'EBN,'K&N
MK]YZ5\>\F.L,# +"?=U"EWHIJA: 9O(9L;P(]%46@E0IMO>75S==BT]B<[%)
M_#7#*1%;_@]02P,$%     @ XX%56IZ($HI*"   +V,  !4   !A=&YF+3(P
M,C4P,C$U7W!R92YX;6S5G6UWVC84Q]_OG'T'C[TF/*39UK393DI##V=MDP7:
M;GO3(VP!.A$21Y(3^/:3#": +?FR!Z[7%RDQ5]+]_ZXLZ]J2\_J7Y9Q'CU1I
M)L55HW/6;D14Q#)A8GK5^#1L7@][@T$CTH:(A' IZ%5#R,8O/W_[363_O?ZN
MV8SZC/+D,GHKX^9 3.2KZ".9T\OH'154$2/5J^@SX:D[(ON,4Q7UY'S!J:'V
MBW7#E]'%6?=B'#6;@'H_4Y%(]>E^L*UW9LQ"7[9:3T]/9T(^DB>I'O19+.>P
M"H>&F%1O:VLOVYM_Z^*O.1,/E^['F&@:65Y"7RXUNVJX=C?-/IV?235M==OM
M3NOW#^^'\8S.29,)QRVFC;R4JZ6L7.?ERY>M[-O<M&"Y'"N>MW'>RMW9UFR_
M90'['4\TN]29>^]E3$P6]LIF(J^%^ZV9FS7=H6:GVSSOG"UUTLCA9P25Y/2>
M3B+WOXW>MM7.3VW.)E3'S'8\FL6MY6Q:/6G[I74X*SU3='+5($9,;"/=BW:W
M<^&:^'[/R*P6MG]JYKI7(VKM-;]05%-A,L7O[8&](G1I;*^B25Z1:_](!PTS
MKLRFZW2BINMGZ=PV:3^N+3?^Y!YQ&>\YP5T\Y('BO&]GU#6-SZ;RL9509NEW
M7[@/#L>+#(7]Y6O6T/58&T5BD]?$R9CRK/ZOUN; I/6/O9H0/<XZ1*J;4T(6
M:]<H-SH_\NSCYL!7=\Y1!V=$QBY6!4<WAH=VA][N1O5:[7M.5)Q7;#_NA;38
MCS<6K051MKYF/&-\VQLF2LY]^#8-RJ#74B54V=&UW4;G;;L^'=B/&L!\QQ:9
MNX=K&/Z.^YL =&L0@!XG6M].AD;&#]=+!HE#L<C_,1Q%%=O3 BLHNRZ]E7/"
MA#\:9;8U"X.O:QU$I$S))A1_-Q+%Z_+UZ&/?7HWF<RFRANZ(RN97[3-W=;RC
M:CBSVC[0^?CY$KH#W14'EZX*P_;L_X\"X.]&.?FCY!1ZS;\9DB]$*2*,'LF[
M5,4S.VG+VK;N[_@7#,M1-0!#<XX;FK\!Y9^&Y\AY73Z7'-D:RZ=U^Q9 [O\5
M=O]T(\=>\!@%Z[5M/W$^]#F9EG,], &"[:"2+96%A?:MS9P46SA %83W++$'
M]>- EXA$&B'NZ92YY,2YLM40'C(\1;#'[J,&D:!LI%!<"Y$2?D\74E5$8-\2
M"/Y%+<"7B43B_5M*E*&*KR#("\9 ZA>UH.Z1BC4KL;,GS1PH"/FB-1#]#[5
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MI?[%&.664-*X.61()=KX/ 6-S],CQV?<7-*G#@GR>NV\/<=NQYQ-B7]_7K
M>*]2+= '-)]Z>V2V;<J]ADC-,S_Z]D,Y?X\IE#SR5M20SE,S3Q-F:+)VJ<\$
M$;'-T;8R/#< JDM!(X&\5Q6H'N6YPQ?*^:]"/HDA)5H*FJQ3AM"C!V\1:#CJ
M\-RS0C=*+#Y+GEI<*EL-JSQGA<<4RKX.SSL].G$6H*[7>F^O3^MWTH70^TI
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M LI;N)+<,X+A\2[WB+?H.0KA?9^T*X##2&7N]SV$3 ^<;DEQ3_G6-POR,0K
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MWE@I/XC,E,WJ9M(+NN2]T!:W-*Y*;\OL.HD^X?F(5;&HIV\-8Z0A/&IS&FR
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M.Y:-MJ!N>*[OPT$[81<<@-!#(#43$S!6)Q3+^FXW0#.@B+E7M'"*[%_Z8'C
MVCYN%:]SFR$.X("@%$/WR9M1+KD.A!:(_CJZ.4(*2&1A?#2,?+H)'HC#;X4#
M<"@:VBO/#8?2*X^<:OJ&&=&/</5A SKEF@;B.R'2.$)7W8@]P*[E#8I9M_#T
MM%7,F;Z:WHLVQ,21O*,>;>D#B'QV 8=(FID :BE+ =<(X&AL 4[; ?@X>P?T
MI;/7KFT*:_7$,<I%9 Z)Y$H/FT7U*A[5M%>X1+',G6D4=W@#IR6@K.TBI1YQ
M0^P:P*Z584IA XO(A$(.-V5V35QXIY,F@!/<0Q^/[/4I@*,SO)=OE7P\+PQK
M>8ZB* 6KU@D!;\!69?::QV3YG4\BDL0E)>S_]C%@@EP(9B<+AS80&1T*;@G?
MN[[ZQ#X &C'H'>738'MGNF_J/PA66^XBS1G8CR\B+6"?#._G\&9$][A%F(KU
M;+>3DA\YE$PQGCZWS<CFAM\"&5_V?5UK=FP7-/ZI:WSO<X#T'?K=CN#Y8YL0
MBUVF@&!<$X[ Q[@5&AX82(LP _0EC J,(UY>$.I[D5#3P\ =D.<>[RHMVS3$
MD>'Z00F,/-G9 / 06#J:*?B.T;?XB'@%=P_&C@WOE$R@5-UCOHZ/GI+QMSBE
M5C]@Y^2M^/NXO,P"'S"J 7V\C)M A8/VD[T41O(NURR1BRT<IK\P*-!PP/!3
M"?NLZ8'N,-1'!Q%59RXBH)9*OJE1E K^;TT+_@V(.RW$0.N R!*PO-/Q!@B*
MSI=2BH.\0CTA/5YV+*TTDL]GKC?&J,2-8Y&2"&3A#ZE@\=>7(%C :"=EES<E
MS7.!,73/1"D83U760'U8$628>12>_$78L<%ZDM%[M PV6A=-:1W!$S1&1#MP
M]/U=S[%T4D4DJ:^$EI9*"%9#J4EEC(!G?31Y0B)NF?R=<O]3X0&@G#@%DQ=*
MI^2/&5DDC:K(=;#IL!]22MKR*J+IQ39T1^-44(76&GI^Z1#=LXU5 Y3I57)R
M?>M$/6?E$C)!SS+0;!S@GY>$2&.=XC.FB.+V4$)EAF'\4+C&(N\&M(UMXI#7
M4EB6X9]67"])638M)^>8#E2(Z-,L8(7] [3EH:D&!GFOS]Z$=GS@1<"536WM
MXA@C1A,=/9D[T"1X^"C*(<9AMD1:1B1B8AFC0KX4<,WN&#-':J=YV=5,2$:3
MP=T.V*RZ9;)_[A:Q42O>DJ)O;= :,+T.X@F/ M/851">H?!!QZ[WG5X><_Z]
M&->7B1<H#FS(!G]DANL#A =60Y ,57(!;K ,4WOR(R7_K$L@<**BB)A:7=@Y
MI_9:4I9A"@PG2@<URR"@ X1$I:0$9CLP:E9V7D*.H6_XA>Y?FWHR)!M5A^!O
MU#4Z"#A,AU'I'I7GI<ZAXSHA!K^%.0]BBV@1_Y3Q6#Q<CPN7$N/=NM^G"-J/
M$%4 DI\VD_Q$$ UF%U7?*&K K>N*>*B.GBSFOL"(A35L%S^0IWQ=<+-Y@.][
M9'_+@'Q4Y9)9$0?!KK1$#,<A3]MS*5Y+Z'%FC(IQ0:<L'O5T_'X]"V'_PN52
M]#]%_D]('WW$0,9(B#)Q+D@K2E[,%9L,.0JX#2FK&(<+B=/&G)(LF:'_K%6)
MO\,AG!RE[-5*1(HP@FZ2(S< 66Y70:5-D#:T[+NBT.%)G1*&Q,F8(A2M>4B(
M63<,,(>#X1(\AWT6I8YQ'I/K 0F#87_B4YP8_D[N/4:,#1TO^ >3*65G=34]
M7762DU$'NS)T%/@@7BG;$^E/$O6J<#@ENQN"$ Y8U/] 6I+BFU&IV!!-DDJI
MXV)ID<!UE([P,\:DJ$*9HD-4\#HMB0[PE:AZ;55C!8\5!&SH\VRM%"%(&W!,
M&><U312[ S]WPXJT;Z)<PQ5U#'AY'$6^1_?+.U,LE]71<I5\M7^@;5A6@A@
M,2,KJF=</+/.NF LB,05NIQ%)LL_4-2/=%NZ,SHIB"95X\/H;XF/.A1%286&
M6S4\H;)&KBUB)"ZVB0Q";V@%H(&*H-_TT"3ZM'R/@W;VXP"M^#7NABGW %8%
MGQ#N/ PP!9.,14)E+VBM=;'C)3)7^CG0H!6A2*=\-H;0NKIE4X&HAPG)T <X
M%Q\%UI3HHL4F*F69-R37(&JSJ;*(FH(O[K&B9U2RJK!'_K8M,!$D)GSQL28#
M4\<(J\B9B0"4R%\#2Y(25\04%0+HL85,._L1<C_P%4K(D$&$C!+TZ? >P$[T
MX$7H@;DQ_D5G*[]XD:?RIQ"$FD2 2UE ?(_,.C_LH'6%]H9F8_ 0:VT<H*-)
MQNH&Z!1P$;%@?/;N3L0L$8@NH-1/DD0^\<1TF)/!!N'G<XPBJC!L49I''*T[
M/QP.;8O^2NO3]S(XRK-1DK45$<$6Q)V)V*!-$V&4-Y=%6&Q(#>RXKTE+R^!@
MX>#Y1I2!D)'8%Z1!_DTQ=\YDT-PD:[@-VM@0=1@G#H;7/:::>5S@PI.,\@=M
MW?D&9T8;D245:E51%B8"J& C#% Z=BT/_MM#PE<;DOH))EA@WQ4IFX'H-5"Q
M%#&=8?GRE :*4G5#E(K%Q$>DA20/WFX(>\UAX(2.@CDL+\65PG>%.7(&HCJQ
MG!!+5[H@9W$+VBI;0 </*R@![2B@-AI5221D#1%U>![A-W=KE.@!R@X#%7 1
MV'Q"YM))6J9'EI(_WU1""R36UT2@:'5E*X>F2!*E,KFO72[JE2I4ED@_X6F'
MCL>M00=\4N( 49JDZ8;AA>A?AX%Z&80-*DQ9[!1%BIZPX9NN7O+# 3F<@JUG
M^ZA"5,VIWM'CJ:@::HFZI;C02)Y/>G5MR=6QPG9HB7"1,)')L \"#-F:5,0$
M\V^00HLKG5A.I9/2'&O6._E:K5JNI2Y) ^ KSI6HF2HF#!B)4MQ9:A<4R,1;
MN2LN$]W%28&;PDGFQ!Z411[ISLS"9%CC3]XKE?>J_\E[/29]6H<;_-FBI 29
ML'3A1!,73A[ZNE8A6UWVTTNMH*[.G63A"L7C-U-FMK9B3B=*WB3O[,A,3[Q2
M+6>EV*#/O]M#OH*JGQ3!U=0:5Z)B2DARE8!,P(C5,I@Q8GD9(S''ZODB,4Z[
M]Y21W--262,T.:;@2!R)QX<@2.5]%7#M.)IUH@B,S+=E3U3"A+-,@R=.^!U8
MFSOBTM-Z%P0N"**9>WU<YOC%526/N&(B\4CD.G6^VL+<HW(B$WG(:2I9D(J4
M V8D(F-"U>;E(>>P3C(5V>& *:KQBOT6E8JNJ<0DTKK<F'#11?I2%<UI#?'F
M]G(I3+9B"C.;HT@%D:.K*G1#"]PSRHI@P"0^$Q1V>#V#OMB*CEK"+Y/+S\.6
MB.8$S.8Z^)@RJ)T->4@HN&,J+P=7*6;V)FO/,#Y/D3&'CT4 71:O*:^1T.(Z
MG,IV1=I%W*,96EX*;A!=Y Z)=)@G+Z;!M+K]Q+S-.2>H3:6^8PY+);ZG+]+F
MW0%*YKWKF]4H\TUGM9$H<DVL--9]38ZH;:='Q)'AC-1_)N\Z4>@NJO>/I85'
MK<:YF144:VF<8\X?0,O\*OI9D782#$J9.LSD^*GPO0PA)4[4]7)(#ALQ.>@O
M(0U1.A\I*!SB>)6EPM,!;$<$4%0"35VB2J?U\3&%O^+D__SR@LC8HCA_F351
M=YBF)2N/!52P&9' A[6%C+>PX9"D<(S3DQ<69%[7Q.O;<<5Q D'XSP4(BI>A
M&X7 1AT=!3W ;X \Q0R99"^3"RDM;-/L;K5XM\FDAM!\HE!#%)+G(@C++^B@
MESG2>449VO11R9BSC\7;R7*-*"4@$ KG3ENCBA82#&B!ZY[19[4M3.2*79&
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M8,?E/$UYS^C4$JH"O92-Q-?;DHW6]2D.F&*@%&N(/JV!(OCH:P1:CNR*J-9
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MY!IO .WG;6V1-Y7?4_N7^46/)<E_=IVUK=7M^TNY35G]EZ'-2\ID3%JN:[B
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M.;Q^1-FWQM^COIHS,-W="]%-);QPFIJ1B%76_^>S_6?T^T@DB?O=CN!6)<4
MA[#_#R_9L4Y3,3(@6^Y?)Q&.=->HOR4/]QG)R-LB=_<9R[Q0L4C=H$ 0GSDY
M*A)WE1U )96X:TXB.XB?#O\QY\V*9/9>7]J&_K:O_S%'%/"=PI78[8FA2B=O
MON0D@ SA=F"QP2_R".%'_G73XN6BZ?WNVB+W?QHL*LQ+/]=EEN#"ZARFM=_=
M.=Q_V3H\>MTZ/#Y^'H[H&R=E1D#LE!>YR SH*5B@<C22>2R,M!.8@R,4G<$.
MO/IXU;EIWYQ=7DS/Z+WFY*E&?/B-Z]VT G\.5"'OV!^I[(%> #?Q\%AE#_F*
M],%8Y$J@XC%#D::[,>SP9^_.<#9'N2Q$H73V'5=A_A /'VCV[Y#_!5B(3M8'
MY3*$>5WI15C +7 C\^%"SOG16@C^#<;P5GK^%U#FKZ09Z<RHKDI5H:19Z?E?
M;/G_168R%VFT5DLRO276W20^!*_TMX^=B^O%-XA?KK9!_$$NZ-9[N1;:\"S#
M.55C&?VLL_(;5F+U)/(/:0IX-*:<+D?HI9E(9$ET=?W[TT_/8@M/Y_-(9D;R
M_*S\1EY 43W+$@E+D,!L1J=P52[B0N<KO0IWF1#?QZB9L:V>U)(YBFY^]5B
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M\JEY8N'!\WF@T>:8C+#N(\408):$>/EY &*0)6'MH\"$LM4G)&D,/P"C#ES
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M W!8$I:@(2EQ,Y.WV]4DO:*"WS'!2*Z1="-(ZC8GW@<JE7/1B<VTKAQZ=ML
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MCX^Y1FW'YD([V?U5QQ$E 8UZV J/C<@_6B[?V+4,3C:[JJ$7RY)?F8SV=+3
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M4QI=+.12[#Y>\?^D4YVK)%JJ=5@86V@;_(=?OW2/SQ;?$MI]W);01[V\,K\
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MMD69[,>,-E/)Z@JOD=O1,#7$:QB9041FC@#7"@I,E%'KUU^&67*;[6F1$G0
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M-PGAEHYKG]0V]:%)BX%P1E.^E4HN1%G;3 6:\U3]U&=X%_^Z8YD\Q'B%<Y[
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MKZ8A: %CSB?>6EVIE8VW6L6>+;Y3+_<3OG.DG'IIF9Y<T90]NX:FJ.=T6IY
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MPRCBT(S;&+!I2AP-<'AG_AJNRY!"]XZAJ?U]Y03R%]*,\J44 1D:!N_*\>F
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M=Y88LM5)+0X.ZM2MEYM^F5_TLGB*WWTQ+$?)^_\/4$L#!!0    ( ..!55K
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MT[[+7O27*@HD-GJP]U1%.R]/O*7*X,'_P/F=YIF(L[E,5BJ5[58.3\Y4!#_
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M&KX;G&[WT;_(DS3' Z7-$%1X.DSGKV(O"<0NT IZ6O)L'B<4>("PL,J0G)
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M+K*DZ$U5J#*V<?7ALU]M$$?N#"F22MN0.*^5U(/<"BIU8I^N ?6/[BM^?_2
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M;TPZ^/+C!!ZZC(@N,- F(GZ,L2**"]HY[A_SMA.TC>&Z')N.&7P+3P%_7<;
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MSO7I(#K"=!IB/]029N$8CQ<H:<7$RH4);*+1;<=JBEEDQ;QUI0NJ3U;X_+Z
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M2P$"% ,4    " #C@55:ZV<^?V,[  #8PP$ '0              @ $K4
M96$P,C,Q-S4X,#%E>#$P+3%?,3@P;&EF92YH=&U02P$"% ,4    " #C@55:
MN[TCW6=$  "_T $ '0              @ ')BP  96$P,C,Q-S4X,#%E>#$P
M+3)?,3@P;&EF92YH=&U02P$"% ,4    " #C@55:P!IH4YDF  "QY@  '0
M            @ %KT   96$P,C,Q-S4X,#%E>#$P+3-?,3@P;&EF92YH=&U0
52P4&      @ "  O @  /_<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0231758-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20250215"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20250215.xsd" xlink:type="simple"/>
    <context id="AsOf2025-02-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2025-02-15</startDate>
            <endDate>2025-02-15</endDate>
        </period>
    </context>
    <context id="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-15</startDate>
            <endDate>2025-02-15</endDate>
        </period>
    </context>
    <context id="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-15</startDate>
            <endDate>2025-02-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-02-15" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-02-15" id="Fact000004">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-02-15" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-02-15" id="Fact000010">2025-02-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-02-15" id="Fact000011">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-02-15" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-02-15" id="Fact000013">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-02-15" id="Fact000014">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-02-15" id="Fact000015">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-02-15" id="Fact000016">Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2025-02-15" id="Fact000017">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-02-15" id="Fact000018">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-02-15" id="Fact000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-02-15" id="Fact000020">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-02-15" id="Fact000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-02-15" id="Fact000022">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-02-15" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-02-15" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-02-15" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-02-15" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-02-152025-02-15_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000030">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-02-152025-02-15_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-02-15" id="Fact000033">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
